Trade barriers and functional foods — what are the forgone benefits? by Zhang, Sidi
  
Trade Barriers and Functional Foods 
— What are the Forgone Benefits? 
 
 
 
A Thesis Submitted to the College of 
Graduate Studies and Research 
in Partial Fulfillment of the Requirements 
for the Degree of Master of Science 
in the Department of Bioresource Policy, 
Business and Economics 
University of Saskatchewan 
Saskatoon 
 
By 
 
Sidi Zhang 
 
 
 
 
 
 
© Copyright Sidi Zhang, March. 2009. All rights reserved. 
 i 
PERMISSION TO USE 
 
The author has agreed that the University of Saskatchewan and its library may make 
this thesis freely available for inspection. The author further has agreed that 
permission for extensive copying of this thesis for scholarly purposes may be granted 
by the professor or professors who supervised the thesis work or, in their absence, by 
the Head of the Department or the Dean of the College in which this thesis was done. 
It is understood that due recognition will be given to me and the University of 
Saskatchewan in any scholarly use that may be made of any material in this thesis. 
 
Requests for permission to make use of or to copy the material in this thesis in whole 
or in part should be addressed to: 
 
Head of the Department of Bioresource Policy, Business and Economics 
University of Saskatchewan 
51 Campus Drive 
Saskatoon, Saskatchewan 
57N 5A8 
 
 
 
 
 
 
 
 
 
 ii 
ABSTRACT 
 
Functional foods provide positive externality benefits to society through the 
promotion of health benefits that lower the potential of illness for individual consumer 
and reduce the health care costs that are borne by governments. With strong market 
growth and considerable potential social benefits, functional foods appear to be an 
important area for future expansion in the global food market. However, pre-existing 
trade barriers to international commence reduce, or sometimes eliminate, trade in 
functional foods. Given that there are benefits associated with health-giving attributes 
from functional foods, retaining trade restrictions on functional foods may lead to 
additional forgone benefits. 
 
To examine the effects of the positive health benefits arising from functional foods 
when pre-existing trade restrictions are in place, a comparative-static partial 
equilibrium trade model is modified. Four cases pertaining to import restrictions on 
functional foods are examined in the trade model based on two categories: trade 
policies and ability to produce. The theoretical framework provides an illustration of 
the potential welfare benefits forgone from the existence of trade barriers when a 
traditional food becomes a functional food. 
 
Empirical case studies examined canola oil as a functional food. The value of the 
benefits foregone from maintaining trade barriers to canola oil in two countries: China 
and United Kingdom were estimated. In addition, a cost of illness model was used to 
estimate health care savings. The final ratio suggests that existing trade policies 
directly result in non-trivial costs to society. . As a result, current trade regulations 
might be re-evaluated by policy makers to better reflect the evolving markets for 
functional foods.  
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Chapter 1: Introduction to functional foods  
 
 “Let food be your medicine and medicine be your food.” 
— Hippocrates, 400 BC1 
1.1 Introduction 
The presence in the market of foods enriched to improve human health and/or that 
naturally promoted good health is not a new phenomenon. In recent years, however, 
food consumption for natural purposes is increasingly comingled with a desire to 
improve health and well-being (Niva and Mäkelä, 2007). Consumers have expanded 
their interest in food beyond it being solely a source of nutrition to it being a source of 
additional health benefits (El Hafid, 2004). Increasing incomes have made it possible 
for consumers to think more about their broader well-being and they have become 
interested as to whether food can contribute to that well-being. Further, as the 
population in high income developed countries ages, there is a rising demand for food 
products to maintain and improve one‘s health - as an alternative to pharmaceuticals. 
As a result, it is important to take account of these additional benefits in economic 
analysis. This thesis is a first step in incorporating the benefits associated with 
functional foods into the economic analysis of international trade. 
 
1.2 Overview of functional food  
New types of foods designed to promote health or to reduce the risk of diseases have 
been recognized as functional foods since the 1990s (Niva and Mäkelä, 2007). These 
new products are designed to meet specific health concerns by assisting disease 
prevention and helping to promote health. In addition to new products which are 
designed to be health-enhancing, a number of traditional and familiar foods are also 
now considered functional foods as new health benefits been recently discovered 
                                                 
1 As cited in Siegfried Gursche, Let Food Be Your Medicine and Medicine Be Your Food. 
http://www.alive.com/1293a4a2.php?subject_bread_cramb=725 
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(Hasler, 2000). For example, at the annual Frontiers in Cancer Prevention Research 
conference in Seattle 2004 it was pointed out that, an apple a day may be an effective 
approach to cancer prevention (Davis, 2004). Eggs have proved to be an excellent 
dietary source
 
of many essential (e.g., protein/choline) and non-essential
 
(e.g., 
lutein/zeaxanthin) elements that promote optimal
 
health (Hasler, 2000).  
 
Consumers are increasingly interesting in combining their diet decision with the 
promotion of health benefits. Research conducted by the International Food 
Information Council (IFIC) starting in 1996 suggests that consumer demand for 
functional foods has steadily increased and will continue to do so (Schmidt, 2000). In 
2007, the IFIC commissioned its fifth survey on Americans‘ awareness and attitudes 
toward functional foods. This survey revealed that most Americans believe in the idea 
of functional foods and the health benefits they can provide. Consumers retain a 
strong interest in foods and food‘s links with specific benefits that can help promote 
health and reduce the risk of disease (IFIC, 2007).  
 
1.3 Problem statement 
Due to consumers‘ increasing interest in functional foods, there appears to be strong 
market growth and considerable potential for the functional food industry to expand 
into the global marketplace. However, the agri-food sector is one of the most heavily 
protected sectors in the global economy (Gaisford and Kerr, 2001). Trade barriers in 
agriculture are largely historic in origin – they predate the rise of information 
pertaining to the potential benefits of functional foods. The decisions to put trade 
barriers in place were, hence, made on the basis of an acceptable rise in the price of 
food considering only its nutritional attributes. In other words, those imposing trade 
barriers did not at the time consider the forgone benefits associated with health-giving 
attributes. 
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1.4 Objective 
Given that there may be additional benefits forgone from the existence of trade 
barriers, with better information those responsible for trade policy may wish to alter 
their decisions to impose trade barriers on individual food products. This thesis has 
two objectives: (1) to develop a theoretical framework to illustrate the potential 
welfare benefits foregone from the existence of trade barriers when a traditional food 
becomes a ―functional food‖ and; (2) to provide illustrative case studies of the value 
of the benefits foregone from maintaining trade barriers.  
 
1.5 Thesis outline 
This thesis is organized as follows. Chapter 2 consists of a literature review pertaining 
to functional foods. First, the terminology pertaining to functional foods and their 
definitions are introduced. Second, the current state of functional food markets around 
the world is described. This gives a macro-view of the industry globally. Next, the 
health benefits of functional foods are discussed. With information on the various 
health benefits associated with functional food attributes, a better understanding of the 
meaning of ―functional‖ can be attained. Last, health benefit models are reviewed to 
assist in selecting the analytical tools used in the case studies selected for this thesis.  
 
Following the literature review, Chapter 3 fully develops a trade model that explicitly 
incorporates functional foods. Starting with the standard partial equilibrium trade 
model, four cases pertaining to trade restrictions on functional foods are developed 
and analyzed.  
 
Illustrative empirical case studies are provided in Chapters 4 and 5. Canola/rapeseed 
oil with functional attributes is examined as a functional food. By examining markets 
with different trade restrictions for canola/rapeseed oil, estimates of the value of 
additional foregone benefits from the retention of existing trade barriers are provided. 
Sensitivity analysis is conducted for key assumptions made during the benefits 
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calculations. Generally, the estimates of the foregone benefits and health care savings 
are based on published sources. 
  
Lastly, summary, conclusions and suggestions for further research are provided in 
Chapter 6.  
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Chapter 2: Literature Review 
 
2.1 Functional food 
2.1.1 Definitions and distinctions internationally 
Functional food is a concept that is gaining ever wider acceptance around the world. 
There is, however, no agreement on an exact definition (Health Canada, 1998).  
The Bureau of Nutritional Sciences, of the Food Directorate of Health Canada, has 
proposed the following definition: 
A functional food is similar in appearance to, or may be, a conventional food, is 
consumed as part of a usual diet, and is demonstrated to have physiological 
benefits and/or reduce the risk of chronic disease beyond basic nutritional 
functions (Health Canada, 1998, Page 3). 
 
In Canada, functional foods range from traditional food products with 
health-enhancing attributes to new agricultural technologies including GM food 
products (Malla et al., 2007).  
 
Both nutraceuticals2 and functional foods are sometimes classified as ―natural health 
products‖ in Canada. One of the major distinctions is that functional foods remain 
food products during consumption, unlike nutraceuticals which are taken in a 
processed form such as a capsule or oil in medical sized doses. A large number of 
traditional medicines based on herbal and homeopathic preparations fall within the 
scope of ―natural health products‖. Normally, such products are typically available for 
purchase in the ―vitamins, herbs and supplements‖ sections of most Canadian grocery 
stores. (House of Commons, 1998; Health Canada, 1999). Another similar term is 
―novel foods‖. Food that has been genetically modified so that the characteristics of 
                                                 
2 A nutraceutical is 
a product isolated or purified from foods that is generally sold in medicinal forms not usually associated with 
foods. A nutraceutical is demonstrated to have a physiological benefit or provide protection against chronic 
disease (Health Canada, 1998, Page 3). 
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the plant, animal or microorganism have been altered or changed from those which it 
is derived is also called a novel food (Health Canada, 1999). The term would include 
some functional foods. 
 
Currently, the Food and Drug Administration (FDA) in the United States has no 
specific definition or special regulatory regime for foods being marketed as 
―functional foods‖. FDA regulates foods labeled as ―functional foods‖ under the same 
regulatory framework as other conventional foods (FDA, 2006a). Although there is no 
formal definition for ―functional food‖, a report by the Institute of Food Technologists 
(IFT) in the US defined ―functional foods‖ as ―foods and food components that 
provide a health benefit beyond basic nutrition (for the intended population)‖ (IFT, 
2005). 
 
In the US, the term ―Dietary Supplements‖ (usually viewed as nutraceuticals) is often 
used to refer to health-enhanced products. The FDA regulates dietary supplements 
under a special set of regulations that cover both conventional foods and drug 
products (prescription and over-the-counter) (FDA, 1997). Following the definition in 
the US Dietary Supplement Health and Education Act (DSHEA) of 1994, a dietary 
supplement is ―a product taken by mouth that contains a ‗dietary ingredient‘ intended 
to supplement the diet‖ (FDA, 1995). The "dietary ingredients" may include: vitamins, 
minerals, herbs or other botanicals, amino acids, and substances such as enzymes, 
organ tissues, glandulars, and metabolites (FDA, 1995). Dietary supplements can be 
found in many forms such as tablets, capsules, softgels, gelcaps, liquids, or powders 
(FDA, 2001). Under DSHEA, ―dietary supplements‖ is a special category classified as 
foods instead of drugs. 
 
In Japan, policy development in the area of functional foods is directed at ―foods for 
special health uses‖ (FOSHU). Regulated by the Ministry of Health, Labor and 
Welfare (MHLW) in Japan, FOSHU refers to ―foods containing ingredients with 
functions for health and consumed for the maintenance/promotion of health or special 
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health uses by people who wish to control health conditions, including blood pressure 
or blood cholesterol‖ (MHLW, n.d.). FOSHU must be assessed for the safety of the 
food and effectiveness of the functions for health and the claim must be approved by 
the MHLW. 
 
With increasing attention being paid to the concept of ―functional foods‖ and their 
markets, the European Union set up the European Commission Concerted Action on 
Functional Food Science in Europe (FUFOSE). In European Union countries, foods 
recognized as ―functional foods‖ must be normal products that can easily be 
consumed in the diet. A functional food can be a natural food approved as 
―functional‖ or a food with modified components to improve health by technological 
or biotechnological means (EUFIC, 2006).  
 
Although there is no universal definition for the concept of ―functional foods‖, the 
central theme is the same regardless of the exact definition - functional foods are 
introduced into the market as a normal food form in order to promote human health. 
 
2.1.2 Health benefits 
 
“If we are going to live so intimately with these chemicals — eating and drinking 
them, taking them into the very marrow of our bones — we had better know 
something about their nature and their power.” 
                                    ------Rachel Carson, SilentSpring, 1962. 
 
It seems that all foods are functional in that they provide nutrients. However, 
conventional foods become marketable as ―functional foods‖ when they are endowed 
or supplemented with ingredients that contain health benefits beyond basic nutrition 
(NIEHS, 1999). Functional foods are particularly focused on health-enhancing 
ingredients or common components that have potential benefit to human beings.  
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Many foods we eat everyday contain natural components that provide benefits beyond 
basic nutrition. Examples3 of functional foods provided by the International Food 
Information Council (IFIC) can be divided into four categories. Basic foods with 
functional properties (e.g., anti-oxidant beta-carotene in carrots; lycopene in tomatoes; 
omega-3 fatty acids in salmon) are the most common functional food in the daily diet 
of individuals. Some processed foods (e.g., oat bran cereal) are viewed as a second 
type of functional foods which provide functional attributes from their original 
components. Processed foods with added functional ingredients (e.g., 
calcium-enriched fruit drinks) are also recognized as functional foods. Finally, foods 
enhanced to express higher levels of functional components (as through livestock 
feeding or plant and livestock breeding) are also considered as functional foods. (IFIC, 
2000). 
 
Understanding the complex interactions between nutritional components and the 
human body is still in its scientific infancy. However, there is already strong scientific 
evidence that suggests eating foods with functional benefits4 as part of the daily diet 
is a positive way to reduce the risk of, or relieve a number of, health problems such as 
cancer, heart and cardiovascular disease, gastrointestinal disease, menopausal 
symptoms, osteoporosis, eye problems, etc. (NYSOFA, n.d.). For example, lycopene 
in tomatoes and tomato products is well known as a potent antioxidant in protecting 
cells against harmful damage from oxidation. Soy contains hormone-like actors that 
help protect against hormone-dependent cancers such as endometrial and ovarian 
cancers (IFIC, 2001). 
 
New health giving attributes are being identified through ongoing scientific research. 
For example, a new process was recently developed by researchers at the University 
of Maryland which transforms ordinary flour into flour with enhanced levels of 
antioxidants — compounds that have been found to fight against cancer and heart 
                                                 
3 For functional foods and their components, see Appendix 1.  
4 For functional foods and their potential benefits for human health, see Appendix 1. 
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disease. Likewise, scientists at Nihon University in Japan found an easy way to 
remove phytatea — a chemical that is known to hinder absorption of calcium in the 
human body (ScienceDaily, 2006). 
 
With health attributes beyond basic nutrition, functional foods are viewed as a 
convenient food type in promoting health benefits to human bodies. It improves the 
health condition of citizens and reduces health care costs. Functional foods also offer 
a great opportunity to the agriculture and food industry as the potential market for 
functional foods is expanding (AAFC, n.d.). 
 
2.1.3 The functional food industry 
The growth of the functional foods industry provides an opportunity for enhancing 
consumer understanding of the link between diet and disease, analyzing health care 
costs and examining the process of technological improvement in food production (El 
Hafid, 2004). Functional foods appear to be significant in improving the health of 
citizens, reducing health care costs and supporting development in the agri-food 
sector. As a result, food products associated with benefits which enhance human 
health can be identified as a potential growth area for the food industry.  
 
Functional food products represent a value-added growth opportunity for the 
agri-food industry around the world. According to Euromonitor International (2006), 
the world market for functional foods has grown by more than 50 percent in the last 5 
years. The United States, Japan and Europe are major global markets, contributing 
over 90 percent of total sales (Kotilainen et al., 2006).  
 
Healthy foods (natural and organic foods, functional foods and lesser evil foods5) 
sales in the United States reached US $102 billion in 2004. Among them, functional 
foods accounted for 20 percent of total US healthy food sales (excluding food service). 
                                                 
5 Lesser-evil foods are manufactured by removing unwanted substances including fat, calories, preservatives, 
caffeine, alcohol, salt, etc. from their originally state (NBJ,2008).  
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In addition, with increasing concerns regarding human health, the functional foods 
market grew 6.8 percent in 2004 compared to a 1.6 percent growth rate in total food 
sales (NBJ, 2006). Functional attributes are becoming an important factor in food 
market success. The sales of functional and fortified foods were expected to reach US 
$35.86 billion in 2006, up to 22% over 2005, and $59.87 billion in 2009 (Sloan, 
2006). 
 
Japan is the second-largest market in the world for functional products after the US 
(JETRO, 2006). Starting from the early 1980s, functional foods developed rapidly in 
Japan. The government has had a strong involvement in this industry as a result 
Japan‘s aging population with its increasing health problems and the expected future 
increases in health care costs (Kotilainen, 2006). With an ongoing increase in demand 
expected for functional foods, Japan represents one of the most sophisticated markets 
for these products. The Japanese market is valued between US $4 billion and US $15 
billion annually (SWMI, 2002).  
 
The functional food market in Europe is expected to grow quickly — by as much as 
16 percent annually — with approximate value US $15 billion (SWMI, 2002). 
Within Europe, Germany, France, the United Kingdom and the Netherlands represent 
the most important markets for functional foods (Menrad, 2003). In the United 
Kingdom, sales of functional foods and drink were valued at ₤835 million (US $1.65 
billion6) in 2003. The market is forecast to double in the next few years, reaching 
₤1.72 billion (approximate US $3.4 billion) in 2007 (IGD, 2007). 
 
As a whole, the functional foods sector appears to provide a large potential for rapid 
growth in global markets. The market is expected to grow much faster than the overall 
food industry. 
 
                                                 
6 GBP: USD = 1:1.98, based on the current market foreign exchange rate (average, July 7, 2008). 
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2.2 Valuing health benefits 
Correct valuation of risks to human health is essential to health, safety, and the 
environment (Berger et al., 1987). A number of economics studies of health benefits 
have been developed to measure the benefits from health savings. Economic 
evaluation methods considered to take a comprehensive approach include cost-illness 
analysis, cost-effectiveness analysis, cost-utility analysis and cost-benefit analysis; 
while partial economic evaluations depend on cost analysis, cost-comparison studies 
and cost-outcome descriptions (Higgins and Green, 2008).  
 
2.2.1 Cost-of -illness model  
Traditionally, measuring the benefits of improved health has been based on avoidance 
of the damage that occurs as a result of contracting disease (Berger et al., 1987). One 
of the most simple and straightforward approaches to estimate the medical costs 
avoided based on health improvements is the cost-of-illness (COI) model (EPA, 
1991).  
 
Cost of illness studies were first used in the late 1950s and early 1960s and have been 
used extensively since that time (Cooper and Rice, 1976). They are most common in 
the medical literature. The basic idea in COI studies is to estimate the maximum 
economic costs that could potentially be saved or gained if a disease were to be 
lessened or eradicated (Segel, 2006). The cost of illness is measured by the sum of the 
direct costs for prevention, detection and treatment from health care and the indirect 
costs or loss due to disability (morbidity) and premature death (mortality) (Cooper 
and Rice, 1976). A COI study, however, may be conducted in several different ways. 
Each approach in calculating costs may vary due to different perspectives from 
society, the health care system, businesses, the government, and citizens (Segel, 
2006).  
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COI studies are valuable because they provide informative evidence for policy makers 
(Segel, 2006). COI analysis helps policy makers and government make their decisions 
on public programs by showing the financial impact of certain diseases (Bartlett et al., 
1994). For example, a COI model was used by Miller et al. (1998) to estimate medical 
costs borne by US states related to smoking, this strengthened the fight against the 
tobacco industry in state lawsuits attempting to recover losses associated with 
cigarette smoking. Cost of injury studies based on a version of the COI approach can 
also provide information on disease control and prevention strategies which may be 
useful to safety and health professionals (Rice et al., 1989; Biddle et al., 2005). Thus, 
the COI model is a powerful method in addressing important relationships between 
medical incidents and social policy.  
 
2.2.2 Cost-of-illness — an example 
Malla et al. (2007) valued the potential health benefits of trans fat-free canola oil by 
using the COI model. In their paper, a COI model is adapted to estimate the impact of 
a change in dietary fat intake on coronary heart disease (CHD) costs in Canada (Malla 
et al., 2007). Their model is based on an assumption that a 1% drop in the incidence 
of the disease in the long run will result in a 1% decrease in the COI. By including 
direct and indirect CHD costs (i.e., the total cost of illness, disability, and premature 
death) in the calculation, two alternative methods of calculating reductions in the cost 
of illness are embedded in the study. Both approaches followed basic assumptions of 
the COI model, however, Method 1 is focused on total cholesterol level changes 
based on reviews of the scientific literature; while Method 2 concentrated on the 
percentage of energy intake change from a study by the US Food and Drug 
Administration (Malla et al., 2007).  
 
Using the two different calculation methods, Malla et al. (2007) have shown that the 
potential health-care or cost of illness savings in Canada from healthier trans fat-free 
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canola oils are important. The authors suggest valuing health improvements through 
food industry innovations is a subject worthy of further study (Malla et al., 2007). 
 
2.2.3 Assessments of the Cost-of -illness model  
2.2.3.1 Weaknesses of COI model 
There are, however, weaknesses associated with the use of cost-of-illness studies. The 
COI model is developed under the assumption that the impact of a disease is to be 
mitigated or eradicated. However, from the characteristics of diseases, most chronic 
illnesses that generate large medical expenses cannot be greatly reduced or 
completely eradicated. Thus, the ―cost savings‖ estimated by COI studies will likely 
be overestimated under the optimal assumption (Roux and Donaldson, 2004).  
 
In addition, as a basic and straightforward method, a COI model may overlook 
additional information that could be used to better value the impact. Opportunity costs, 
for example, should be considered in a health evaluation to obtain the optimal solution 
for the allocation of resources (Donaldson and Narayan, 1998). Another example is 
the difficulty associated with measuring the utility foregone by consumers in a COI 
model compared to a contingent valuation (CV) model. Based on a survey of 
willingness-to-pay or willingness-to accept among responders, a CV model is superior 
in valuating non-market attributed which give people utility. Without taking into 
account the loss in utility to individuals, the COI model may underestimate the true 
cost of illness. Furthermore, instead of establishing a relationship between costs and 
benefits, the static COI model simply tabulates the two concepts and adds them 
together to establish the net total cost (Roux and Donaldson, 2004). Without the 
appropriate information and a comprehensive treatment, COI studies are likely to be 
sub-optimal in determining how resources are to be allocated (Drummond, 1992.). 
 
Further, the COI calculations must be done carefully to avoid double-counting 
problems (Roux and Donaldson, 2004). Many diseases are connected with each other 
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stemming from a common origin. Simply calculating the total costs resulting from 
certain diseases might lead to underestimation or incomplete analysis (Donaldson and 
Narayan, 1998). 
 
Hence, sensitivity analysis is an appropriate cautionary approach when there is 
uncertainty. By setting several different levels or discount rates as well as ranges for 
other important variables, a range of possible costs would provide more credibility for 
policy analysis (Segel, 2006).   
 
2.2.3.2 Conclusions regarding the COI model 
Although the COI model has several disadvantages, a COI study can be a superior 
method under some conditions. First, by placing emphasis on the whole society rather 
than the individual‘s perspective, the COI model is appropriately designed for a 
public health agency to make their decision (Rice, 1962). Secondly, the choice of 
models is usually limited by the availability of data. The COI model is a simple 
approach that requires little restriction on the type of data that can be used. Thus, a 
COI model is an easy and realistic solution if obtaining the data is a relatively easy 
task compared to other health valuation models (Rice et al., 1989). Moreover, as a 
simple and straightforward model, the COI approach is relatively straightforward to 
calculate and easy to understand (Biddle et al., 2005). If the economic analysis is 
formulated to general questions about health cost impacts, the COI model is likely a 
suitable choice.  
 
In this thesis, the objective is to calculate foregone benefits from international trade 
barriers placed on functional foods in order to provide suggestions for both trade and 
public health policy. Following the trade model developed in the next chapter, the 
health benefit evaluation in the case studies is targeted at a general problem. From this 
perspective, a COI model is viewed as an acceptable analytic tool for fulfilling the 
objective of this study.  
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Chapter 3: Modelling Trade 
and Functional Foods 
 
3.1 Basic model 
There are a number of theoretical and empirical approaches used in economic 
modeling of international trade. A general equilibrium approach is often preferred  
because it captures shifts in resource use and consumption between sectors of the 
economy (Gaisford and Kerr, 2001). A disaggregated, general equilibrium approach 
would be desirable when the trade effects for an entire economy with its multiple 
markets are desired - especially if the cross market effects are expected to be 
important. Unfortunately, general equilibrium models quickly become intractable 
when all but the simplest disaggregation is attempted.  
 
Computer-based computational general equilibrium (CGE) models can be used to 
overcome the limitations of general equilibriums models. CGE models, however, 
have two major practical problems. They can only be undertaken using a high degree 
of aggregation, meaning a CGE model is still limited in valuing the interrelationships 
among sectors. Further, even the simplest CGE models have very high, and costly, 
data requirements (Gaisford and Kerr, 2001). 
 
While the general equilibrium approach has a useful role in evaluating multiple 
markets with different commodities, an alternative but complementary approach 
should be considered if analysis is focused on individual disaggregated commodities 
and where cross-market effects are expected to be small (Gaisford and Kerr, 2001). In 
such cases, a comparative-static partial equilibrium approach to modeling 
international trade relations may be preferable. 
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In this thesis, the objective is to examine the forgone benefits from international trade 
barriers placed on functional foods. The economic analysis is focused on the impact 
of policy changes on specific functional food market viewed in isolation. The 
cross-market effects are expected to be sufficiently small to be safety ignored. 
Therefore, a comparative-static partial equilibrium trade modeling approach for the 
domestic functional food market of an importing country is selected and applied in 
this thesis.. The comparative-static partial equilibrium trade model can be illustrated 
in Figure 3.1.  
 
 
Figure 3.1 Basic trade model 
 
D is the domestic demand curve for a particular product. As the price of the product, P, 
rises, consumers will not be willing to purchase the same quantity as at the lower 
price. Consequently, the quantity demanded, Q, declines and the demand curve is 
negatively sloped. For supply, as the price, P, rises, production becomes more 
profitable and the output supplied by producers increases. Thus, the quantity supplied, 
Q, increases, leading to a positively sloped supply curve, S (Gaisford and Kerr, 2001).  
Q
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Without the opportunity to engage in international trade, the equilibrium price is 
determined where the total domestic supply of the commodity is equal to the total 
domestic demand. At this point, E, the market clears at PE because the quantity being 
supplied by firms, QE is exactly equal to the quantity of the commodity being 
demanded by consumers.  
 
In Figure 3.1 in the autarky case, consumer surplus is represented by area a1 which is 
a triangle above the domestic price and below the demand curve. Producer surplus is 
area a2+a5+a10, a triangle below the domestic price and above the supply curve. 
Combined, the consumer surplus and the producer surplus, make up the total surplus 
or the welfare arising in this market. 
 
Now assume the opportunity to engage in international trade in this product arises. 
The price consumers and producers face in the international markets is Pw — the 
world price. In this case, Pw is the price at which imports can be obtained in the 
international market, Pw < PE. Assuming transport and transaction costs associated 
with international shipments are sufficiently small to ignore, the domestic price will 
decline to equal the world price.  At Pw, domestic consumers are willing to purchase 
Q
D
 while domestic producers are only willing to supply Q
S
. The difference between 
demand and supply at Pw is filled by imports. The import quantity is shown as 
(Q
D
-Q
S
). Consumer surplus a1 +a2 + a3 + a4 + a5 + a6 + a7 + a8 + a9 is a triangle above 
the world price and below the demand curve. Producer surplus is area a10. Total 
welfare is a1 +a2 + a3 + a4 + a5 + a6 + a7 + a8 + a9 + a10 and greater than under autarky 
(i.e. a1 +a2 + a5 + a10 ). Thus, trade is welfare enhancing. 
 
If Pw is too low for some producers to make normal profit, they may lobby for 
protection from imports. Political decision makers may wish to supply protection. 
Protection could be provided through the imposition of a tariff (tax) on imports. After 
the tariff, T, is imposed, the domestic price rises from Pw to (Pw + T). At price (Pw + 
T), domestic firms are willing to produce additional quantity because they must now 
 18 
compete with imports priced at (Pw + T) instead of with imports priced at Pw. The 
supply expands from Q
S 
to Q
S‘
.
 
However, the higher price leads to a reduction in 
consumption from Q
D
 to Q
D‘
. Thus, imports decrease to (Q
D‘
- Q
S‘
). 
 
After imposing the tariff, total welfare also changes. The higher domestic price leads 
to an increase in producer surplus but a loss in consumer surplus. At price (Pw + T), 
the consumer surplus shrinks from area a1 +a2 + a3 + a4 + a5 + a6 + a7 + a8 + a9  to area 
a1 +a2 + a3 + a4 and producer surplus increase from area a10 to area a5 + a10. The tariff 
causes a loss of consumer surplus equal to a5 + a6 + a7 + a8 + a9 for a gain in producer 
surplus of a5. If the objective of the protection policy was to increase producer surplus 
by a5, decision makers must weigh the benefits of producers more heavily than 
benefits of consumers. In this case, we assume that the revenue received by 
government is not a motivation in the decision to provide protection. This is a 
reasonable assumption for most modern market economies where tariffs receipts are a 
relatively trivial source of revenue
7
. In the case of functional foods, the trade 
restricting policies may not be tariffs
8
. Thus, the protection would have been granted 
on the basis of a weighting of consumer and producer benefits only. Let us denote 
  as the ratio giving decision makers‘ weighting of the changes in consumer 
surplus and producer surplus arising from the imposition of a protectionist policy
9
. 
surplusproducer  
surplusconsumer   
 


  
 
Compared to the situation before the tariff, consumers suffer a loss of area a5 + a6 + a7 
+ a8 + a9 and producer gain area a5 . Thus, 
                                                 
7 This may not be the case for some developing countries and the analysis would have to incorporate tax revenues 
for those countries. We ignore these cases. 
8 It is assumed that the rents available from the imposition of non-tariff barriers do not influence policy makers‘ 
decisions. 
9 The ratio will be underestimated without the tariff revenue. The tariff revenue could be used for social welfare 
improvement – an addition to the numerator of the ratio formula. However, the tariff revenue need not be spent in 
the market we are examining and thus would represent a loss to the market. In this thesis, however, tariff collected 
as government revenue will not be considered as part of the policy makers‘ decision to extend protection to 
producers. As suggested above, it might, however, be a factor in the decision process in some developing countries 
and the model used in our analysis would have to be modified in those cases. 
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In order to clarify the effects before and after the granting of protection, let‘s simply 
assume  = 3 for this specific situation. When  =3, the loss for consumers 
arising from the higher price is three times larger than the gain by producers. Political 
decision makers must assign at least three times the weight to producer benefits than 
they assign to consumer benefits. Given that the tariff was imposed, a weight of three 
is the minimum weight they could have used in their decision, although a higher 
weighting may have been possible. While political decision makers may not explicitly 
make these weighed trade offs, they must do it implicitly with some ―rule of thumb‖. 
The change in trade policy turns out to be welfare reducing for the domestic economy 
(Gaisford and Kerr, 2001). If the situation in the market changes such that  rises, a 
case might be made for decision makers to re-evaluate their decisions.  
 
3.2 Four cases for trade barriers applied to functional foods 
This thesis focuses on the trade policy effects when new products with health 
improving attributes — functional foods — become available in markets with 
pre-existing restrictions on trade in place. Functional foods have significant potential 
to improve the health of citizens, reduce health care costs, and support economic 
development (AAFC, n.d.). Functional foods represent a value-added growth 
opportunity for the Canadian agri-food industry, both domestically and internationally. 
As suggested in the previous chapter, the market is large, global and growing 
(Tebbens, 2002). 
 
While the trade barrier in place could be a tariff, non-tariff barriers are also common 
in agriculture (Hobbs, 2007). Food products normally face two broad types of 
non-tariff barriers. One set of non-tariff barriers acts like an import ban — prevents 
any imports. Other non-tariff barriers raise the cost of exporting so that imports still 
take place, but at lower levels — the effect is similar to a tariff (Kerr, 2007). 
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Figure 3.2   Non-tariff barriers effects 
 
Figure 3.2 illustrates the differential effects of a ban compared to an increase in costs 
as a result of an import regulation. Before any import regulation is put into place, 
domestic consumers and producers face Pw, a world price in the international market. 
At Pw, domestic demand from consumers is Q
D
 while domestic supply is Q
S
. The 
difference between demand and supply at Pw leads to imports. The import quantity is 
shown as (Q
D
- Q
S
). However, when there are non-tariff barriers pertaining to imports, 
the market will be constrained. If the non-tariff barrier acts like an import ban, it 
prevents any imports. There is only domestic production sold in the market and 
imports at Pw cannot take place. The market will clear at PE. The equilibrium quantity 
is Q
E
. Thus, equilibrium will be reached at PE, a higher price than Pw.  
 
Non-tariff barriers can also raise the cost of exporting. In such a case, the domestic 
price will increase from Pw to (Pw + C) - where C is the additional cost increase faced 
by the exporter in satisfying the importing country‘s requirements. At (Pw +C), import 
quantity shrinks to (Q
D‘
- Q
S‘
). 
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In order to gain market access, exporters may have to satisfy cost increasing 
regulations of importing countries. An example might be testing to ensure that 
imports are free of a drug residue. These regulations maybe unduly odorous and thus 
provide economic protection — they are a disguised protectionist measure. Thus, 
there are additional costs incurred in the process of production when firms in the 
exporting country wish to export their products. If there are different requirements for 
testing and proof of scientific evidence, the importing country may refuse to accept 
foreign credentials or scientific procedures and the importer‘s regulations are 
equivalent to an import ban.  
 
The welfare effects of a trade restriction also vary depending on whether or not the 
new functional food can be provided domestically in the importing market. Therefore, 
four different cases pertaining to import restrictions on functional foods can be 
examined. These four cases fall into two categories: trade policy and ability to 
produce. Within ―trade policy‖, the focus is on the trade barrier faced by exporters. 
The barrier is either equivalent to an import ban or a cost increasing regulation
10
. 
Under ―ability to produce‖, functional foods are divided by the ability to acquire the 
new products from domestic producers as well as imports (domestic production or 
imports) or solely from imports (imports only).   
 
 
 
 
 
 
 
 
 
                                                 
10 Tariffs are treated as part of the latter category.  
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Table3.1 Four cases for trade policy and the supply of functional foods 
 
 
Cost increasing regulation Import prohibition 
Domestic production  
or imports 
Case 1 Case 2 
Imports only Case 3 Case 4 
 
Table 3.1 outlines the four cases under different trade policy and production 
constraints. Case 1 and Case 3 are based on the same trade policy but different 
assumptions regarding the ability to produce. Products in Case 1 can be supplied by 
domestic producers and obtained from the international market. On the other hand, for 
Case 3 the functional food version of the product can only be acquired from the 
international market. In Case 2 and Case 4 the supply choices are the same as above 
but the market is constrained by the more restrictive policy such that imports are 
effectively banned.  
 
3.2.1 CASE 1 
For Case 1, there are both domestic sellers and an international source of supply for a 
new functional food — an innovative product.  
Trade 
Policy 
Ability 
to produce 
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Figure 3.3 Case 1 — domestic and import supply, cost increasing regulation 
 
Figure 3.3 shows the domestic market of the conventional product as well as 
functional food. D
M
 is the demand curve for a pre-existing product M that does not 
have health enhancing attributes. There is a supply curve S
M 
for product M. At Pw, the 
world price for M, consumers are willing to purchase the product M at Q
DM 
and 
producers will only supply Q
SM
. Imports would be (Q
DM 
- Q
SM 
). If a cost increasing 
import restriction has been put in place that raises costs so that the ―landed price‖ 
equals (Pw + C) — cost increasing regulation (or equivalent tariff) — imports will fall 
to (Q
DM‘
- Q
SM‘
). 
 
The cost increasing policy will alter welfare in the market. Without the regulation, the 
consumer surplus is area a1 +a2 + a3 + a4 + a5 + a6 + a7 + a8 + a9. Producer surplus is 
shown as area a10. After trade policy is implemented, consumer surplus decreased to 
area a1 +a2 + a3 + a4. Consumers suffer a loss of area a5 + a6 + a7 + a8 + a9 in consumer 
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surplus because of the higher price. On the other hand, producer surplus increases to 
an area a5 + a10 — a change equal to a5. The relative weighing ratio is 
5
98765
M          
surplusproducer  
 surplusconsumer   
 
a
aaaaa 



  
 
Now assume a new health enhancing functional food version of product M, denoted 
product N, comes onto the market. In order to simplify the exposition, we make three 
assumptions. First, we assume the new product, N, can be produced at the same cost 
as product M by both domestic and foreign suppliers. Second, product N can be 
represented by the same demand curve as product M and that the new health attribute 
does not change the slope of the demand curve in a meaningful way.
11
 Thirdly, from 
the perspective of consumers, more people are willing to buy the new health 
enhancing product N at the same price. Therefore, demand increases shifting out the 
demand curve from D
M 
to D
N 
. As the additional demand can be accommodated by 
acquiring additional imports at (Pw + C), there is no change in price. Thus there is no 
change in domestic producer surplus. 
 
The new product, N, faces the original world price Pw and distorted landed price (Pw + 
C), the same as with product M. With the new demand curve, consumers receive more 
surplus than that from product M. With no trade restriction, consumer surplus changes 
from area a1 +a2 + a3 + a4 + a5 + a6 + a7 + a8 + a9 to area a1 +a2 + a3 + a4 + a5 + a6 + a7 
+ a8 + a9 +a11 + a12 + a13 + a14 an increased benefit of area a11 + a12 + a13 + a14.  After 
the cost increasing trade policy is applied, new world price (Pw + C) leads to a decline 
in consumer surplus to area a1 +a2 + a3 + a4 + a11 + a12. Therefore, the cost increasing 
policy generates a loss in consumer welfare of area a5 + a6 + a7 + a8 + a9 + a13 + a14. In 
addition to the direct consumer benefits from functional foods which arise in this 
market, there may be savings in health care costs
12
 for the government as a result of 
                                                 
11 It is possible that the slope of demand curve for product N will be changed due to a technology innovation in 
production of N or a change in consumer‘s perception of the product. As no information is available on how the 
slope may have changed, a parallel shift in demand is assumed in this thesis. 
12 Health care costs include direct health care cost such as inpatient care cost and out patient care cost as well as 
indirect health care cost such as loss in productivity and informal care. 
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the consumption of the functional food. We assume for the moment that these cost 
savings are a positive constant denoted HCS
13
. The relative weighting ratio is now at 
least 
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Therefore,
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As a result, policy makers may wish to revisit their decision to impose a trade barrier. 
 
3.2.2 CASE 2 
For Case 2, there still exist both domestic producers and international sources of 
supply for a new functional food — an innovation product. However, the new 
functional food, N, faces a regulatory trade barrier that is equivalent to an import ban.  
                                                 
13 This assumption will be relaxed at a later stage. 
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PN 
 
Figure 3.4 Case 2 — domestic and import supply, trade prohibiting regulation 
 
Figure 3.4 illustrates the domestic market when a new functional food enters the 
marketplace. As in Case 1, D
M
 is the demand curve for a pre-existing product that 
does not have health enhancing attributes, product M. S
M 
is the domestic supply curve 
for product M. At Pw, the world price for M, consumers are willing to purchase Q
DM 
and producers will only supply Q
SM
. Imports would be (Q
DM
- Q
SM 
). The consumer 
surplus is area a1 +a2 + a5 + a6+ a7 + a8 and the producer surplus is area a9.  If there is 
an import ban imposed on product M, the price will rise to P
E
M and the quantity 
consumed will be Q
EM
. Therefore, the consumer surplus will decrease to area a1 +a2 a 
reduction of a5 + a6+ a7 + a8. Producer surplus increases to area a5 +a9 with an 
increase equal to area a5. 
 
The relative weighting ratio is 
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Now product N — a new health enhancing version of functional food — arrives in the 
market. Our two assumptions still hold: (1) The new version product, N, can be 
produced at the same cost as product M by both domestic and foreign suppliers and; 
(2) product N can be represented by the same demand curve as well as same slope as 
product M and; (3) more consumers are willing to buy the new health enhancing 
product N at the same price. Therefore, the new health enhancing functional food, N, 
shifts demand curve out to D
N 
. Product N faces the same world price as product M. 
At Pw, the consumer surplus increases to area a1 +a2 + a3 + a4 + a5 + a6 + a7 + a8 + a10 + 
a11. As the world price is unchanged and supply curve is not altered, domestic 
producer surplus remain equal to area a9.   
 
With the import ban in place, the domestic price rises to P
E
N and the quantity 
consumed equals to Q
EN
. At P
E
N, consumer surplus decreases to area a1 +a10.  
Consumers suffer a loss of area a2 + a3 + a4 + a5 + a6 + a7 + a8 + a11 in consumer 
surplus because of the higher price. On the other hand, new producer surplus 
increases to a area a2 +a3+ a5 +a9 — a change equal to a2 +a3+ a5.  Again, there may 
also be a health cost savings — HCS.  The relative weighting ratio is 
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It is an empirical question whether 
N   
>  
M  
or  
N   
<  
M
 or  
N   
=  

M
 due to the different producer surplus change in the denominator of our weighting 
ratio formula. It is possible that 
N  
>  
M
 . So, policy makers may wish to 
reconsider the imposing import ban after the introduction of the health-enhancing 
functional food. 
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3.2.3 CASE 3 
For Case 3, there is only an international supply for a new functional food. Figure 3.5 
shows the domestic market of both conventional product and the new functional food 
version of the products. Before the new innovative product enters into the market, the 
situation for the original product M is the same as in Case 1. D
M
 is the demand curve 
for a pre-existing product M and the supply curve S
M 
for product M. At Pw, the world 
price for M, imports would be the difference between what consumers are willing to 
purchase, Q
DM
, and what producers will supply, Q
SM
 , that is (Q
DM
- Q
SM 
) . If a cost 
increasing import restriction has been put in place that raises costs so that the ―landed 
price‖ equals (Pw + C), imports will fall to (Q
DM‘
- Q
SM‘
).
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 Figure 3.5 Case 3 —import supply only, cost increasing regulation 
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The cost increasing policy will change the welfare in the market. Without the 
regulation in place, the consumer surplus is area a1 +a2 + a3 + a4 + a5 + a7 + a8 + a9 + 
a10 + a11 + a12 + a13 + a14 + a15 + a16 and producer surplus is area a6. However, after 
trade policy is implemented, consumer surplus decreased to area a1 + a2 + a3+ a13 + 
a14 with a loss of area a4 + a5 + a7 + a8 + a9 + a10 + a11 + a12 + a15 + a16. In contrast, 
producer surplus increases to area a4 + a5 + a6 + a7 + a8 + a10 — a gain equal to a4 + a5 
+ a7 + a8 + a10.  The relative weighting ratio is 
 
108754
161512111098754
M
      
                 
surplusproducer  
 surplusconsumer   
 
aaaaa
aaaaaaaaaa





  
 
Now assume the new version of product M — a health enhancing functional food N 
— comes onto the market but can only be sourced from imports. Our three 
assumptions: (1) new product, N, can be produced at the same cost as M by foreign 
suppliers and, (2) product N can be represented by a demand curve that has the same 
slope as product M. (3) more people are willing to buy the new health enhancing 
product N at the same price, still apply here.  
 
To begin with, product M and N are facing the same world price at Pw with no trade 
barrier. At any price above Pw, no consumers are willing to purchase product M. 
Based on assumptions, consumers switch to the market for N, which shifts the 
demand curve from DM to DM
1 
in the market for M. This unambiguous switch to 
product N will continue until curve DM reaches DM
3
. The difference between demand 
curve DM and DM
3
 leads to a separate market for N. In the market for N in figure 3.5, 
we take DN
1
 for the demand curve of product N when the demand for product M is 
DM
3
. Once the demand curve for M shifts further left of DM
3, product M‘s price will 
be less than Pw and some consumers will choose to continue to consume it. This 
means that the rate that consumers are switching to product N slows. The further to 
the left the demand curve for M moves, the larger the price advantage for product M 
and the more attractive product M will be to consumers. An equilibrium may well be 
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reached somewhere between point D and F in figure 3.5. If the demand curve for M 
reached DM
4
, no firms are willing to supply product M. At point F, the market for M 
no longer exists and all consumers have moved to the market for N. 
 
 
When there is a cost increasing restriction in place, the demand will again shift in as 
consumers switch to the more desirable product, N. When demand for M reaches DM
1
, 
point A in figure 3.5, product M and N both face price (Pw + C). The difference 
between demand curve DM and DM
1
 leads to demand curve DN for product N in the 
separate market for N. 
 
After point A, the demand curve of M still shifts in because consumers might be more 
interested in the new version of the product with functional attributes. However, it is 
possible that domestic producers can supply product M at a lower price than (Pw + C). 
Therefore, some consumers may stay in the market for M because it is lower priced 
than N. Let‘s suppose the price of M declined to PE
M,where DM
2
 equals S
M
. Point B, 
may be an equilibrium if no more consumers are willing to switch to product N. As 
more consumers switch from M to N, the demand curve for N shifts out from DN in 
Figure 3.5. Finally, the demand curve in market for M could reach DM
4
 and the 
demand curve in market for N will move to DN
2 
in figure 3.5. At point F, there is no 
supply for product M and consumers will all have switched to the market for N. 
 
As the demand changes are dynamic, we calculate the welfare of both consumers and 
producers based on minimum changes at demand curve DM
1 
(point A and G) for the 
maximum change at demand curve DM
4
 (point F). In both markets together, 
consumers receive more surplus than that arising from only product M being in the 
market — N gives more utility per unit than M. At point G, without trade barrier, 
consumer surplus equal area a1 +a2 + a3 + a4 + a5 + a7 + a8 + a9 + a10 + a11 + a12+ b1 + 
b2+ b4. However after the cost increasing trade policy is applied, at point A, new 
world price (Pw + C) makes consumer surplus changes to area a1 + a2 + a3+ b1 with a 
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loss in consumer welfare of area a4 + a5 + a7 + a8 + a9 + a10 + a11 + a12 + b2. The 
change of producer surplus remains a4 + a5 + a7 + a8 + a10. 
 
The relative weighting ratio is now at least 
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where only product M available at the domestic market. 
 
Noticing that (a4 + a5 + a7 + a8 + a9 + a10 + a11 + a12) is common term in both 
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M
. Therefore, 
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As a result, political decision makers may wish to reconsider their decision to impose 
a trade barrier which adds to the cost of imports. 
 
At point F in figure 3.5, without a trade barrier, demand in market for product N has 
shifted to DN
2
 and consumer surplus equals area b1 +b2 + b3 + b4 + b5 + b6 + b7  
However after the cost increasing trade policy is applied, new world price (Pw + C) 
makes consumer surplus changes to area b1 + b3 + b6.with a loss in consumer welfare 
of area b2 + b4 + b5 + b7. From the producer side, at point G, the producer surplus is a6 
before any policy applied. After the cost increasing regulation is implemented, at 
point A, the producer surplus is equal to a4 + a5 + a6+ a7 + a8 + a10 with a gain of a4 + 
a5 + a7 + a8 + a10. Nevertheless, the producer surplus is decreasing with the movement 
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of demand curve for M. When the demand curve for M moves from DM to DM
2
, that is 
from point A to point B, the producer surplus changes to a5 + a6 + a8 with a reduction 
of a4 + a7 +a10. Compared to the producer surplus before product N entering into the 
market, calculated as a6, however, producers still gain a5 + a8 if there is no trade 
restriction existing in the market.  Once the demand curve shifts to point D, the 
producer surplus returns to a6 which is exactly the same as when only product M was 
available in the market without any trade restriction. Thus, producers do not receive 
any benefits from the trade restriction policy at point D. From Point D to Point F, the 
producers lose surplus from the arrival of the new good in the market. The price 
increasing policy provides no benefit to producers after point D is reached, and 
consumers suffer a loss in consumer surplus because of the cost increasing regulation. 
Thus, the policy has no merit and should be abandoned.  
 
3.2.4 CASE 4 
In Case 4, while there is domestic market to supply the conventional version of 
product, no domestic capacity to supply the functional food exists. The new products 
can only be acquired from the international market. However, the new functional food 
can‘t be acquired from aboard because of an import policy that is equivalent to a ban. 
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Figure 3.6   Case 4 —import supply only, trade prohibiting regulation 
 
Figure 3.6 give us an insight into the domestic market before and after introducing a 
new functional food product. As in the previous cases, D
M
 represents the demand 
curve for a pre-existing product that does not have health enhancing attributes, 
product M. S
M 
is the supply curve for product M. At Pw, the world price for M, 
consumers will purchase Q
DM 
and producers are only willing to supply Q
SM
. The 
difference between demand and supply would be (Q
DM
- Q
SM 
) for imports. Thus, the 
consumer surplus is area a1 +a2 + a3 + a4 and the producer surplus is area a5.  As in 
case 2, if there is a import ban imposed on the product M, both consumers and 
producers will reach the new equilibrium E
M
 with P
E
M, a higher price than Pw, and 
quantity Q
EM
. Therefore, the consumer surplus will decrease to area a1 with reduction 
of a2 + a3 + a4. Producer surplus changes to area a2 +a5 with an increase of area a2. 
The relative weighting ratio is 
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If the new health-enhancing product N can be introducing into the domestic market 
successful through imports, there will be a demand shift from the original demand 
curve D
M 
to D
N 
. From our previous assumption, product N can be produced at the 
same world price as product M. So, at Pw, there is larger demand, Q
DN
, for the new 
product. However, in this case, there is no domestic production of product N that can 
be supplied to the consumers. Thus, the total imports are equal to total demand Q
DN 
. 
The consumer surplus expands to area a1+ a2 + a3 +a4 + a6 + a7. 
 
However, in case 4, we assume there exists an import regulation that still acts like a 
ban, thus allowing none of product N into the market. The demand for product N 
cannot be supplied by the international producers. Thus, the new demand curve, D
N 
, 
does not apply under an import ban. The domestic market has to move back to the 
previous situation with the product in an autarky market.  
 
We assume there is no supply of the old product M from foreign market — the 
exporter no longer produces product M. Thus, consumers and producers return to the 
domestic price P
E
M. At the autarky equilibrium point, consumer surplus decreases to 
area a1, a reduction of area a2 + a3 +a4 + a6 + a7 and the producer surplus is area a2 + a5. 
There would also be a health care savings equal to HCS. Therefore, the relative 
weighting is 
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 Thus, 
N
>  
M  
. 
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Therefore, political decision makers may wish to change their trade inhibiting 
policy.  
 
3.3 Health care costs 
In each case, we assumed that the HCS is constant. However, savings in health care 
costs for the government is not likely to be a constant. In most cases, it is likely to be 
some function of the consumption of the particular functional food. Following our 
analysis in every case, the HCS that would arise from the remove of the trade barrier 
is a function of the increased consumption of product N. That is, 
 HCS = ƒ( ΔQN ),where ΔQN is the difference between the consumption of N 
with a trade barrier and that which arises without the trade barrier.  
 
HCS will be different depending on each case given the different trade situations 
illustrated above. In Case 1, there are both domestic sellers and an international 
source of supply for functional food N. The cost increasing regulation increases the 
import price from Pw to (Pw + C) which leads to a reduction in the demand of product 
N. Thus, the difference between the consumption of N with a trade barrier and that of 
without a trade barrier is measured by the quantity change along the demand curve D
N 
from (Pw + C) to Pw.  
HCS
1
 = ƒ( ΔQN ) = ƒ(QDN - QDN‘)  
 
In Case 2, product N faces both domestic and international supply but with a 
regulatory trade barrier that is equivalent to an import ban. The import ban leaves no 
supply for product N from the international market. Thus, the difference between the 
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consumption of N with a trade barrier and that without the trade barrier is measured 
by the quantity change on the demand curve D
N 
from Pw to P
E
M.  
HCS
2
 = ƒ( ΔQN ) = ƒ(QDN – QEN)  
 
In Case 3, there is only an international supply for functional food N. Like Case 1, the 
cost increasing regulation makes the import price Pw increase to (Pw + C) which leads 
to a reduction in the demand of product N. Thus, the difference between the 
consumption of N with a trade barrier and that without the trade barrier is measured 
by the quantity change along the demand curve D
N 
from (Pw + C) to Pw. As the figure 
in Case 3 is dynamic, the change in consumption of the product N, which based on the 
shift of demand curve D
N 
, can‘t be calculated precisely.  
HCS
3
 = ƒ( ΔQN ) = ƒ( ΔQN ) ≥ ƒ(QN - QN‘)  
 
In Case 4, there is no domestic capacity to supply the functional food N. However, 
product N cannot be acquired from abroad because of an import policy that is 
equivalent to a ban. Before the import ban, the consumption of N is based on imports 
only and the import quantity is equivalent to domestic demand which is Q
DN
. With the 
import ban in place, the imports of product N do not take place. Therefore, there is no 
consumption of product N. The change in the consumption of product N is just equal 
to Q
DN
. 
HCS
4
 = ƒ( ΔQN ) = ƒ(QDN - 0)  
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3.4 Summary 
This chapter has developed a partial equilibrium model to examine the effects of the 
introduction of functional foods that provided consumers with positive health benefits 
when pre-existing trade restrictions are in place. In order to illustrate the model‘s 
usefulness in the next two chapters, two case studies are used to provide empirical 
evidence of the value of forgone health benefits. 
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Chapter 4: Chinese Case study 
4.1 Introduction 
Over time, consumers have responded to new scientific information related to food   
consumption by switching consumption to products with healthier or less harmful 
components (Malla et al., 2007). Recently, the relationship between consumption of 
trans fatty acids (TFA) and associated heart disease has become a hot topic with the 
public. Coronary heart disease (CHD) refers to the failure of the coronary circulation 
system to supply adequate blood to the heart muscle and surrounding tissue. Over 
451,000 Americans die of coronary heart disease every year (AHA, 2008a). In the 
United Kingdom, over 100,000 deaths annually are attributed to coronary heart 
disease (BHF, 2007). Scientific studies suggest that consumption of trans fat will 
increase the risk of CHD. The Food and Drug Administration (FDA) in the United  
States ruled that the reporting of trans fat levels had to be added to the Nutrition Facts 
Panel on food labels starting from January 1, 2006. Identifying saturated fat, trans fat, 
and cholesterol on the food label provides consumers with information so that food 
choices that help reduce the risk of CHD can be made. The revised label was expected 
to be helpful to people who are concerned about high blood cholesterol and heart 
disease (FDA, 2003a).  
This chapter provides a Chinese case study to examine the potential welfare benefits 
forgone from the existence of trade barriers when a selected product becomes a 
functional food. First, the chapter gives a detailed overview of the connection between 
trans fat and health. Further, the selected product —  canola/rapeseed oil is 
introduced from two aspects — its functional attributes to reduce the risk of CHD 
and its current market in the international trade. Following this introduction, the 
empirical case study of Chinese canola/rapeseed oil is examined according to Case 1 
in the framework developed in Chapter 3.The forgone benefits of functional 
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canola/rapeseed oil in China arising from the trade barriers — a high tariff are 
calculated.  
 
4.2 Trans fat and health 
Trans fat (also known as trans fatty acids) is a specific type of fat formed when liquid 
oils are processed into solid fats like shortening and hard margarine. However, a small 
amount of trans fat is naturally occurring, primarily in selected animal-based foods. 
The majority of trans fat comes from adding hydrogen to vegetable oil through a 
process called hydrogenation. Trans fats are more solid than oil but less likely to spoil. 
In processed foods, trans fat helps food keep fresh, extends the self life and gives 
products a less greasy feel (MFMER, 2006). 
 
Animal-based fats were once the only trans fats consumed, but by far the largest 
amount of trans fat are formed during the partial hydrogenation of vegetable oils, a 
process that converts vegetable oils into semisolid fats for use in the food industry 
(Mozaffarian et al., 2006). The FDA in the United States estimates that animal-based 
fats constitute only 21 percent of the TFA intake, with hydrogenated vegetable oil 
representing the main source of TFA in human diets (FDA, 2005). Besides animal fat, 
24 percent of TFA intake is from visible fats such as margarine, shortening, and salad 
oils (17%, 4%, and 3%, respectively); the rest (55%) is consumed through fast food 
products and processed food items like bread, cookies, chips, candy, etc. (FDA, 
2003b).These partially hydrogenated fats have displaced natural solid fats and liquid 
oils in much of the human diet, notably in fast foods, snack foods, fried foods and 
baked goods.  
 
Production of hydrogenated fats increased steadily as a healthy alternative to animal 
fats due to their being unsaturated and being available at lower cost. As early as 1988, 
however, scientific studies suggested that trans fats could be a cause of the large 
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increase in coronary artery disease (Booyens et al., 1988). Additional studies over the 
years have confirmed this finding. The consumption of trans fatty acids raises the 
levels of low-density lipoprotein (LDL) cholesterol
14
, so called bad cholesterol and 
reduces levels of high-density lipoprotein (HDL) cholesterol
15
, so called good 
cholesterol. Trans fats alter the ratio between LDL and HDL by decreasing the ratio 
HDL in total cholesterol
16
. The latter is a powerful predictor of the risk of CHD 
(Stampfer et al, 1991). Trans fats also increase the levels of triglycerides
17
 in the 
blood when compared with the intake of other fats (Mensink et al., 2003), increase 
levels of Lp(a) lipoprotein
18
 (Ascherio et al., 1999) and reduce the particle size of 
LDL cholesterol
19
 (Mauger et al., 2003), each of which may further raise the risk of 
CHD.  
 
A study published in the New England Journal of Medicine reported that trans fat is 
linked to a 93 percent rise in the risk of cardiovascular disease. The research also 
revealed that replacing of 2% of trans fat consumed with monounsaturated fat 
(MUFA) that are derived from plant sources such as canola, peanuts and olives could 
reduce heart disease risk by 53 percent (Lam, 2002). 
 
4.3 Selected product 
4.3.1 Healthy choice-Canola oil 
Canola was developed from rapeseed plants by Keith Downey and Baldur Stefansson 
in the 1970s (MCGA, n.d.). Using the selective breeding method, canola was created 
by lowering the anti-nutritional components erucic acid and glucosinolates in 
                                                 
14 LDL (bad) cholesterol could lead to heart attack or stroke by forming clots in the inner walls of the arteries and 
blocking the way to feeding the heart and brain (AHA, 2008b). 
15 High levels of HDL (more than 40 mg/dL) protect against heart attack by carrying cholesterol away from the 
arteries to the liver, where it is passed from the body (AHA, 2008b). 
16 The total cholesterol to HDL cholesterol ratio is obtained by dividing the total cholesterol value by the value of 
the HDL cholesterol. High ratios (High total cholesterol and low HDL cholesterol) indicate higher risks of heart 
attacks (Kinosian et al., 1994). 
17 Triglyceride is a form of fat made in the body. High triglyceride levels may cause heart disease (AHA, 2008b). 
18 Lp(a) lipoprotein is a genetic variation of LDL (bad) cholesterol. A high level of Lp(a) is a risk factor for the 
heart disease (AHA, 2008b). 
19 LDL particles carry the LDL through the bloodstream. Smaller LDL particles may more easily become trapped 
in blood vessel walls than larger ones, possibly increasing risk for heart disease (UWNEWS, 1999). 
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traditional rapeseed plants so that it would be absolutely safe for human and animal 
consumption (Canola Council of Canada, 2008a). In order to differentiate this product 
from rapeseed, the word "canola" was derived from "CANadian Oil, Low Acid" in 
1978 (Klahorst, 1998).  
 
Natural rapeseed oil, also called ―industrial rapeseed oil‖ contains at least 44 percent 
erucic acid (high-erucic rapeseed oil, HERO), which is mainly used as an additive in 
animal feed (Piazza and Foglia, 2001). Only small quantities can be added to animal 
feed. By introducing an edible form of rapeseed that is low in erucic acid and 
glucosinolates, rapeseed production via canola has experienced significant growth in 
the past forty years (Walker, 1999). This may cause confusion as the term ―rapeseed 
oil‖ is sometimes used without specifying its erucic acid content. Since some 
countries still apply the term ―rapeseed oil‖ when identifying low-erucic rapeseed oil 
(Canola oil), the term ―rapeseed oil‖ when used in this thesis specially refers to 
low-erucic rapeseed oil, known in some markets as Canola oil. HERO will be used if 
high-erucic rapeseed oil is discussed. 
 
Conventional canola oil and soybean oil require hydrogenation to make them stable. 
Hydrogenation is the process that turns fats into trans fat. New technology, however, 
gives canola oil a very high degree of stability, eliminating the need for hydrogenation 
(Malla et al., 2007). At present, there are two types of canola oil: commodity and 
high-oleic. The former is sold directly to consumers; the latter is characterized by high 
stability which is newer and sold almost exclusively to food processing companies 
and food service operations. Both oils have the same low level of saturated fat and 
positive health attributes (Canola Council of Canada, 2008b).  
 
The FDA (2006b) states that:  
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Limited and not conclusive scientific evidence suggests that eating about 1½ 
tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart 
disease due to the unsaturated fat content in canola oil. (n.p.) 
 
Thus, Canola oil is seen as a healthier alternative to a number of important vegetable 
oils due to its trans fat-free and very low, or even zero, saturated fat but high—almost 
60%—monounsaturated oil content and beneficial omega-3 fatty acids profile. 
Saturated fat has been linked to rising levels of bad LDL cholesterol in the blood and 
increased risk of CHD. Monounsaturated fat is helpful in reducing the risk of 
coronary heart disease and controlling blood glucose by lowering bad LDL 
cholesterol in the blood. Omega-3 fats are essential for a healthy daily diet and it 
helps protect against heart attacks and strokes. Thus canola oil might be a better 
choice in avoiding trans fat in deep fried and baked foods and is becoming a popular 
oil of choice in restaurants and commercial food products (Canola Council of Canada, 
2008c).  
 
As outlined in Chapter 2, functional food is defined by Health Canada (1999) as a 
food product that has physiological benefits and/or reduces the risk of a chronic 
disease beyond that provided by a basic nutritional function. As one of the healthiest 
oils in the marketplace with zero trans fat and cholesterol, canola oil may result in 
health benefits and medical cost savings by reducing the potential risk of coronary 
heart disease in addition to any nutritional value derived from its consumption. 
Therefore, canola oil can be recognized as a functional food. 
 
Currently, Canola oil represents approximately 70 percent of the vegetable oil 
consumed by Canadians. Only 25 percent of the seed that is produced each year is 
required to satisfy the domestic market. Nearly 75 percent of the canola seed, oil and 
meal produced in Canada are exported to destinations such as the United States, Japan, 
Mexico, and China (CanolaInfo, n.d.). However, export markets do not provide 
barrier free access to Canadian canola products. Tariff and regulatory costs raise the 
landed price of canola, which reduces consumption in import markets. Imports are 
 44 
banned by some countries. Requirements in some countries limit the canola varieties 
that Canada can export. Testing requirements for de-registered varieties and pesticides 
that can be used on canola are being increased in some countries. (Canola Council of 
Canada, 2008d). Removing bans and opening up markets for genetically modified 
(GM) canola products is still a slow process in European Union counties.  
 
Thus, canola oil, with it functional attributes, also suffers from export barriers to 
market access. Hence, it is an appropriated product to use for the case studies in this 
thesis.  
 
4.3.2 Canola/Rapeseed oil market  
Due to the recent expansion of the bio-fuels sector and the growing health concerns in 
North America as well as continued economic growth and the rising population in 
Asia (AAFC, 2007), since 2000-2001, the world vegetable oil sector has been 
growing at a rapid rate. For 2006-2007, the value of world vegetable oil trade is 
expected to exceed the value of world trade in wheat and be more than twice the value 
of the trade in corn. The percentage distribution of vegetable oils by type is:  palm oil 
(31%), soy oil (29%), canola/rapeseed oil (15%) and sunflower seed oil (9%) (AAFC, 
2007). 
 
World Production of canola/rapeseed oil is expected to rise to 18.2 Mt
20
 in 
2006-2007 (AAFC, 2007). The EU is the world‘s largest producer of canola/rapeseed 
oil at 6.8 Mt, China is in second place at 4.6 Mt, India produces 2.2 Mt while Canada 
is the world‘s 4th largest producer of canola oil at 1.5 Mt. Canada is the world‘s 
largest exporter of canola/rapeseed oil, accounting for approximate 60 percent of 
world trade. The US is the world‘s largest importer of canola oil, which is primarily 
used in salad and cooking oils. Imports into the US were approximately 0.8 Mt for 
                                                 
20 Mt: Million tonnes. 
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2006-2007. The EU is the world‘s second largest importer of canola/rapeseed oil — 
0.5 Mt for 2006-2007 (AAFC, 2007). However, these European imports are primarily 
used in the rapidly growing biodiesel sector because Canadian canola is produced 
using genetic modified plants, which had faced a de facto import ban
21
 in the past and 
in meeting the current regulatory hurdles due to ongoing food safety concerns over 
GM technology in the EU. 
 
4.4 Chinese case study 
4.4.1 The Chinese vegetable oil market 
The market for vegetable oils is growing across Asia as a result of expanding 
populations and rising incomes. China‘s population growth rate is approximately 8.6 
million people per year. Further, gross domestic product (GDP) in China is growing 
by 10.5 percent annually in 2006. Per-capita GDP in China is approximately 
US$7,600 on a purchasing power parity basis (AAFC, 2007). Given a tight 
international market for edible oils, in 2007, the Chinese oilseed market reached 
historically high price levels. According to the China State Administration of Grain
22
, 
total vegetable oil imports reached 8.5Mt in 2006-2007, accounting for 18 percent of 
global imports of vegetable oils. However, the annual consumption of vegetable oils 
increased to 23.4Mt, meaning only 15.14Mt are being supplied domestically. The 
consumption of canola/rapeseed oil is 4.34 Mt and domestic production only supplies 
4.01 Mt at the existing price level (USDA, 2008). As a result, approximate 0.33 Mt 
total of canola/rapeseed oil are imported. This is approximately to 15% of the world 
canola/rapeseed oil imports. 
 
Since the 1990s, China has had an import management control system for vegetable 
oils. A tariff rate quota (TRQ) restricts the amount of vegetable oils that can be 
imported. All imports up to the quantity limit known as the ―TRQ-quota‖ are subject 
                                                 
21 de facto moratorium means that no commercial releases of genetically modified organisms (GMOs) have been 
approved from1998 to 2004. The releases include new authorizations on adoption of rules, marketing and labelling 
of biotechnology products (Baumüller, 2004). 
22 State Administration of Grain can be accessed at: http://www.grain.gov.cn 
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to a low ―within-quota tariff‖ of 9 percent, while any additional imports are subject to 
a higher ―above-quota tariff‖ ranging between 19.9 percent and 52.4 percent (Xu and 
Wang, 2006). From 2006, however, China removed all of the import management 
restrictions on vegetable oils as part of its WTO accession commitments. However, 
there still a flat tariff rate of 9 percent on imports of vegetable oils.  
 
Recall from the model developed in chapter 3, in Case 1, there are both domestic 
producers and international source of supply for a functional food. China‘s current 
import regime is consistent with Case 1. In the China case study, canola/rapeseed oil 
is a new identified functional food with extra health benefits. Given the constraints on 
Chinese production and processing capacity, imports of canola/rapeseed oil are 
required. However, the existing tariff level still acts as a trade barrier on imports. As 
developed in the case 1, tariffs restrict trade and protect the domestic market by 
raising the domestic price in the importer‘s market. The protection benefits producers 
at the expense of consumers. There is an overall welfare loss because the gain of the 
producer surplus cannot offset the decline in consumer surplus. This tariff was put in 
place prior to the health benefits of canola becoming apparent. Given that the social 
costs can be expected to rise as the health benefits become known, the Chinese 
government may wish to revisit having a tariff on canola oil.  
 
Canola oil is selected as the product to be examined for in the case study. Oil is the 
final consumer product from which the health benefit is derived. Of course, canola 
oilseed is the major traded product. Since the focus of this thesis is on the forgone 
benefits of trans fat free canola oil from existing trade barriers, the calculations will 
not address trade canola oilseed directly because oilseeds are semi-finished products 
that need further processing into oil and meal. The import data used in the Chinese 
case study are estimated through domestic production and consumption for oil – they 
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are net oil import quantities. The benefits consumer and health care cost savings are 
derived from oil consumer by those living in China.
23
  
 
4.4.2 Case study calculations  
4.4.2.1 Trade effects calculation 
Recall from Case 1 in chapter 3, in Figure 4.1, D
M
 is the demand curve and S
M
 is the 
supply curve for canola/rapeseed oil before people realize the health benefits it 
provided. At world price Pw, consumers are willing to purchase Q
DM 
and domestic 
producers will only supply Q
SM
. Imports would be (Q
DM 
- Q
SM 
). However, a 9% 
import tariff is in place in China. It raises the domestic price above the world price so 
that the new domestic price equals (Pw + C). Imports will fall to (Q
DM‘
- Q
SM‘
). 
 
* In order to calculate the area, a5 is divided into a5a and a5b.  
Figure 4.1 Case 1 — domestic and import supply with tariff in China  
                                                 
23 If one wished to calculate the benefits for exporters, the proportion of trade arising from oil imports and seed 
imports that would be processed into oil would have to be considered. As there is a degree of tariff escalation in 
Chinese tariffs, using the tariff on oil may overestimate the trade benefit to some degree. 
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Without the tariff, the consumer surplus is area a1 +a2 + a3 + a4 + a5 + a6 + a7 + a8 + a9. 
Producer surplus is area a10. After the tariff is implemented, consumer surplus 
decreased to area a1 +a2 + a3 + a4. Consumers suffer a loss of area a5 + a6 + a7 + a8 + 
a9 in consumer surplus because of the higher price. On the other hand, producer 
surplus increases to an area a5 + a10 — a change equal to a5. 
 
As pointed out in section 4.2.1, canola/rapeseed oil can be seen as a functional food in 
the current food market in China. Keeping the same assumption as in Case 1, more 
people are willing to buy the canola/rapeseed oil with health enhancing attributes that 
are newly recognized by the public. Alternatively, consumers are willing to pay a 
premium for a higher quality (health enhancing) product. Therefore, demand increases 
shifting out the demand curve from D
M 
to D
N 
. As the additional demand can be 
accommodated by acquiring additional imports at (Pw + C), there is no change in price. 
Thus, there is no change in domestic producer surplus. 
 
With the new demand curve, consumers receive more surplus than before. With no 
tariff, consumer surplus changes from area a1 +a2 + a3 + a4 + a5 + a6 + a7 + a8 + a9 to 
area a1 +a2 + a3 + a4 + a5 + a6 + a7 + a8 + a9 +a11 + a12 + a13 + a14, an increased benefit 
of area a11 + a12 + a13 + a14. After the tariff is applied, new world price (Pw + C) leads 
to a decline in consumer surplus to area a1 +a2 + a3 + a4 + a11 + a12. Therefore, the 
tariff generates a loss in consumer welfare of area a5 + a6 + a7 + a8 + a9 + a13 + a14. 
 
Thus, without new health information regarding canola/rapeseed oil, the direct 
welfare changes arising from the tariff are areas a5 + a6 + a7 + a8 + a9 — the decrease 
in consumer surplus and a5 — the increase in producers surplus. Both a5 + a6 + a7 + 
a8 + a9 and a5 are trapezoid areas that can be divided into rectangles and triangles for 
the calculation of their values. Assume that over the relevant ranges, the supply and 
demand functions are linear. After health enhancing attributes of canola/rapeseed oil 
having been accepted, the trade change for consumer is area a5 + a6 + a7 + a8 + a9 + 
a13 + a14 while the increase in producer surplus remains a5. Area a5 + a6 + a7 + a8 + a9 + 
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a13 + a14 can be divided into rectangle a5 + a6 + a7 + a8 + a9 +a13 and triangle a14. 
Combined with the data from Table 4.1, the calculations and resultant values can be 
found in Table 4.3.  
 
Table 4.1 Market data of canola/rapeseed oil in China (2006-2007)
 a 
 
Total consumption (Mt) - Q
DM‘
 4.343
 b 
Domestic supply (Mt) - Q
SM‘
 4.013
 c 
Supply elasticity - 
S   0.32 
d 
Demand elasticity - 
D  -0.20
 e 
World price($ US dollar/tonne) – Pw 852 
f 
Tariff rate 9%
 g
 
tariff cost ($ US dollar/tonne) – C 76.68 h 
Total consumption (Mt) without tariff - Q
DM
 4.415
 i
 
Domestic supply (Mt) without tariff – QSM 3.907 j 
Demand increasing rate
 k
 Base 20%
 
High 50% 
Medium 40% 
Low 10% 
Increased domestic consumption (Mt) 
- (Q
DN
- Q
DM
)
 l
 
Base 0.883
 
High 2.207 
Medium 1.776 
Low 0.441 
a 2006-2007 is from October, 2006 to September, 2007.  
b Source: United States Department of Agriculture (USDA), Foreign Agricultural Service, July 2008.  
c Source: USDA, Foreign Agricultural Service, July 2008.  
d Note: it is a short-term supply elasticity for national rapeseed supply. (Source: Shen, 2007)  
e Note: it is a direct price elasticity for oilseed oil demand. (Source: Meilke et al, 2001)  
f Average price from October, 2006 to September, 2007. Rotterdam CIF, Any Origin, Oil World. Source: USDA, 
Foreign Agricultural Service, July 2008. 
g Source: China Customs.. 
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h Cost - C = P w * 9%.  
i QDM is calculated from following steps using demand elasticity: 
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j  QSM is calculated from following steps using supply elasticity: 
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= 3.907 (Mt)                            
k Demand shift rate is estimated from current reports and studies regarding to China‘s functional food market. For 
details, see section A2.1 in Appendix 2.  
l (QDN- QDM) = demand shift rate* (QDM ) 
 
Much of the data used in the Chinese case study calculations are derived from 
previously published sources including the demand and supply elasticities used. The 
elasticity of demand in the Chinese case study was obtained from Meilke et al. (2001). 
In their model, a direct price elasticity is used for the vegetable oil demand equations. 
Although, canola/rapeseed oil is one of the five major oilseeds products in the world 
(the others are soybeans, cottonseeds, peanuts and sunflower seeds), it only accounts 
for 12% of world consumption (Meilke et al., 2001).  
 
The supply elasticity used in the Chinese case study was obtained from Shen (2007). 
In her analysis, supply elasticity is calculated for the supply response to price changes 
for rapeseed production in China. However, the elasticity of supply is for rapeseed 
production rather than rapeseed oil so that there might be some divergence between 
them.  
Since both the elasticity of demand and supply are derived from previously published 
studies, there is a need to check the robustness of the results in the case studies. Hence, 
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a sensitivity analysis is conducted at both higher and lower levels. Table 4.2 shows 
the trade effects ratio under different elasticity values in Chinese case study. In the 
sensitivity analysis in Chinese Case study, the final ratio 
M
 is 0.003 larger (smaller) 
than its original value. The results indicate that the trade effects ratio is not 
particularly sensitive to the different elasticity values. The impact of elasticity values 
on the trade effects ratio is small, a change of 0.2 percent. Therefore, the original 
combination of demand and supply elasticity can still be used in the Chinese case 
study without any particular concerns.  
 
Table 4.2  Sensitivity analysis for elasticities in the Chinese case study 
 
 
 D  QDM (Mt) S  QSM (Mt) 
M
 
Original 
level 
-0.20 4.415 0.32 3.907 1.106 
Higher level
（+20%） 
-0.24 4.429 0.38 3.887 1.109 
Lower level 
(-20%) 
-0.16 4.400 0.26 3.927 1.103 
 52 
Table 4.3 Trade effects calculation in Chinese case study
 a5 + a6 + a7 + a8 + a9 a5 a5 + a6 + a7 + a8 + a9 + a13 + a14 
 
Rectangle 
a5 + a6 + a7 + a8 
Triangle a9 Rectangle a5a Triangle a5b 
Trapezoid 
a5 + a6 + 
a7 + a8 + 
a9 
Parallelogram 
a13+a14 
Formula Q
DM‘
* C 1/2*( Q
DM
 - Q
DM‘
)* C Q
SM
 * C 1/2*( Q
SM‘
 – QSM)* C  ( QDN - QDM)* C 
Calcu- 
lation 
4.343 * 76.68 
1/2*(4.415- 4.343)* 
76.68 
3.907 * 76.68 
1/2*(4.013- 3.907)* 
76.68 
 
High 
2.207* 
76.68 
Medium 
1.776* 
76.68 
Base 
0.883* 
76.68 
Low 
0.441* 
76.68 
Result 
(Million$) 
333.021 2.750 299.589 4.064 335.771 
High 169.26 
Medium 135.408 
Base 67.704 
Low 33.893 
335.771 303.653 
High 505.031 
Medium 471.179 
Base 403.475 
Low 369.664 
 
5
2
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Table 4.3 shows all the calculations and results for the trade effects of canola/rapeseed oil. 
According to above table, with the 9 percent tariff rate on import of canola/rapeseed oil in 
China, consumers suffer a loss of US$335.8 million in consumer surplus change (area a5 
+ a6 + a7 + a8 + a9) because of the higher landed price. On the other hand, producers gain 
US$303.7 million in producer surplus change (area a5). Results indicate that the 
consumer loss is larger than producer gain.  
 
After health information regarding canola/rapeseed oil becomes well-known to the 
Chinese consumers, consumers‘ loss increases, but producer gain remains constant. For 
the four levels of demand shift under the sensitivity analysis in appendix 2, a US$403.5 
million in base level, a US$505 million in high level, a US$471.2 million in medium 
level and a US$369.7 million loss in low level in consumer surplus change (area a5 + a6 + 
a7 + a8 + a9 + a13 + a14) have been calculated in Table 4.3. At the base level of demand 
shift, for example, consumers suffer a US$403.5 million reduction in consumer surplus 
because of the increased consumption of canola/rapeseed oil. This loss is increased about 
20 percent compared to the former US$335.8 million consumer surplus change. High 
level represents around 50 percent increase compared to previous situation. Even at lower 
levels, increased consumption of healthy canola/rapeseed oil leads to a much greater loss 
in consumer surplus than when the health benefit was unknown. As expected, the results 
of trade effects indicate that the tariff generates a larger loss in consumer welfare than the 
gain on the producer side. The loss becomes even larger after the increased consumption 
of canola/rapeseed oil with health attributes are taken into consideration.  
 
4.4.2.2 Estimating the Potential Health Care Cost Savings for the Chinese Case 
study 
There are a variety of methods used in health economics to measure the potential benefits 
of improved health. They include costs of illness (COI) (consisting of medical 
expenditures and forgone earnings), household production of health and preventive 
expenditures (Berger et al., 1987), willingness to pay, cost-benefit analysis, and 
cost-utility analysis (Gyrd-Hansen, 2003). 
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In this chapter, the model developed by Malla et al. (2007) is adapted to estimate the 
potential health benefit and related medical cost savings arising from the consumption of 
more healthy trans fat-free canola oil. Malla et al. (2007) use a variation on the COI 
approach to estimate the impact of a change in dietary fat intake on CHD costs in Canada. 
Drawing heavily on the model developed by Malla et al. (2007), their method is 
developed in four steps (See Figure 4.2). The calculation will start from the trans fat 
intake reduction caused by the substitution of a trans fat-free canola oil for other 
vegetable oils to the effect of reduced cholesterol levels on the incidence of CHD in the 
studied country and from there to the relationship between CHD and medical costs 
savings. Following Malla et al. (2007), it is assumed that a 1% drop in the incidence of 
the disease in the long run will result in a 1% decrease in the COI. 
 
Figure 4.2 Steps of COI model analysis 
 (Source: Malla et al., 2007) 
 
Step 1: Estimate possible daily trans fat intake reduction due to ‗trans fat-free canola oil 
in China 
In step 1, a total trans fat consumption (intake) per day is estimated using available 
studies. Due to different diets and eating habits, calculations and results vary among 
countries. 
Step 1: Estimate possible daily trans fat intake reduction 
due to ‗trans fat-free canola oil in the studied country 
Step 2: Calculate cholesterol change (LDL & HDL) due 
to reduced trans fat consumption 
Step 3: Calculate CHD risk reduction due to changes in 
the cholesterol profile 
Step 4: Calculate health cost changes (HCS) from 
reduced incidence of CHD 
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In China, there is no database for TFA consumption. Therefore, detailed research studies 
on citizens‘ daily TFA intake do not appear to be available. Generally in China, the total 
fatty acids in the daily diet come from natural fatty acids in food and from vegetable 
based cooking oils that contain very low TFA. In general, the Chinese diet leads to a 
lower intake of shortening oil when compared to diets in North America and Europe. 
According to FAO (2006) statistics, however, there is an increasing trend for both 
production and consumption of fats. The average fat consumption (g/person/day) in the 
world increased 1.3 times from 1979-1981 to 2001-2003. In China, the rise of fat intake 
has been dramatic increasing 2.7 times from 33g/person/day to 90 g/person/day over the 
same period (FAO, 2006). With rising incomes and the opening of the economy, Chinese 
dietary tastes are broadening. The dietary structure is changing from traditional oriental 
cooking towards diverse dining. North American and European food and fast food in 
particular, is becoming increasingly popular. While no studies on fat consumption in 
China could be found, the TFA intake of the daily diet in China is increasing due to rising 
shortening oil consumption, especially among young people. 
 
While no studies on trans fat consumption in mainland China could be found, a study on 
trans fats in locally available foods conducted jointly by the Centre for Food Safety (CFS) 
and the Consumer Council (CC) in Hong Kong, China is available. The study tested a 
total of 80 products which, for the most part, use hydrogenated vegetable oils (shortening 
oil, salad oil and margarine) in their production. Samples included (i) bakery products 
(including breads, cakes, egg tarts, chicken pies and batter-made food such as egg rolls, 
waffles and egg puffs); (ii) deep fried foods (including French fries, fried chicken, pork 
chops, fritters and pastries); and (iii) butter and margarine/margarine-like spreads were 
collected for testing. The study found that trans fats levels varied considerable among 
similar food products. For example, trans fats levels in 23 bread samples ranged from 
zero to 1.8 g/100 g. Trans fats levels in 11 butter-made products ranged from zero to 1.0 
g/100 g. For the 14 fried products, there was also a wide range of trans fats levels from 
0.034 to 0.38 g/100 g. These results suggest that it is possible to reduce trans fats levels 
in food products (CFS, 2007).  
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Following the CFS (2007) study, a total trans fat consumption (intake) per day in daily 
food sources can be estimated. The estimated average consumption used in the case study 
on China is 1.99 g, including 0.54 g/day from baked goods and 0.03 g/day from 
butter-made products, 0.03 g/day from fried products and 0.39g/day from margarine/ 
margarine like spreads
 24
. 
 
Table 4.4 Trans fatty intake reduction in China due to trans-fat-free canola oil  
 
 Base High Medium Low 
Total TFA intake daily (g) in sample foods 
a
 1.99 1.99 1.99 1.99 
Assumed TFA reduction (%) in sample foods 
b
 20 50 40 10 
Total TFA reduction (g) in sample foods
 c
 0.40 0.99 0.79 0.20 
a The Total TFA intake daily (g) in sample foods is calculated in Section A3.1 in Appendix 3.  
b TFA reduction (%) in sample foods is assumed to have four levels from high, medium, and base to low. These four 
levels indicate the percentage of vegetable oils found in daily food consumption that is assumed to be replaced by 
trans fat-free canola oil. The TFA reduction ratio guarantees the subsequent calculations focus solely on the health 
care cost savings for a certain group of people who consumed trans fat-free canola/rapeseed oil rather than other 
vegetable oils. 
c The total TFA reduction = The Total TFA intake daily (g) * Assume TFA reduction (%) 
 
From Table 4.4, the effect of trans fat-free canola oil substitution can be seen. Using 
sensitivity analysis, the estimation assumes four level of substitution from base (20%), 
high (50%), medium (40%) and low (10%). The resulting reductions in trans fat 
consumption are 0.40 g (Base), 0.99 g (High), 0.79 g (Medium) and 0.20 g (Low) daily in 
China.  
 
Step 2: Calculate cholesterol change (LDL & HDL) due to reduced trans fat consumption 
According to Malla et al. (2007), a number of studies have measured the effects of TFA 
consumption on LDL, HDL, and total cholesterol levels using controlled diets. Following 
Malla‘s conclusion, in step 2, the assumption is made that for every 1 g reduction in TFA, 
total cholesterol will reduced by 1.55 percent. 
 
                                                 
24The main TFA intake in China is assumed from the above categories - baking, butter-made fried products and 
margarine/margarine like spreads. The average calculation method was used for TFA intake in each category. For 
details, see Section A3.1 in Appendix 3.  
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Step 3: Calculate CHD risk reduction due to changes in cholesterol profile 
Drawing on the conclusions of the US National Cholesterol Education‘s Expert Panel 
(Expert Panel, 1988), the assumption can be made that there is a 2% reduction in the risk 
of CHD for every 1 percent reduction in cholesterol levels for the medium, base and low 
cases, while for the high level a 3 percent reduction in CHD risk is assumed (Malla et al., 
2007).  
 
Step 4: Calculate health cost changes from reduced incidence of CHD 
The final step in the analysis (step 4) is to calculate the potential health-care cost savings 
from trans fat-free canola oil.  
 
According to the World Health Organization (WHO), globally, cardiovascular diseases 
were the number one cause of death in the past and remain so currently. An estimated 
17.5 million people died from cardiovascular disease in 2005, which accounts for 30 
percent of all global deaths. By 2015, an estimated 20 million people will die from 
cardiovascular disease (mainly from heart attacks and strokes) if current trends continue 
(WHO, n.d.). In China, the annual deaths due to cardiovascular disease are about 3 
million, accounting for 45 percent of total deaths in the population (NCCD, 2005).  
 
Treatment of cardiovascular-related diseases is also a major cost in China. In a Chinese 
government cardiovascular report, it was estimated that in 2003, the direct cardiovascular 
disease expense
25
 accounted for 16.13 percent (RMB 92.6 billion, approximate US $13.2 
billion
26
) of total health care costs. According to the prediction in the report, CHD costs 
have increased at an average annual growth rate of 12.83 percent over the last 10 years. 
Currently, CHD costs are ranked in the second place in the total medical expense in 
China. The overall health care costs for CHD is around RMB 26.4 billion (US $3.85 
billion) with RMB 13.3 billion (US $1.94 billion) for outpatient care
27
 and RMB 
13.1billion (US $1.91 billion) for inpatient care (NCCD, 2005). Due to absence of 
                                                 
25 Direct costs of CHD represent the value of resources spent that could have been used for other purposes in the 
absence of illness (e.g., hospital expenditures, drug expenditures, medical care, and research) (Malla et al, 2007). 
26 USD: CNY = 1:6.86, based on the current market foreign exchange rate (2:00pm, July 7, 2008). These exchange 
rates apply for all exchange calculations between US dollar and Chinese Yuan in this thesis. 
27 Outpatient care includes outpatient care, emergency medical treatment and medications.  
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indirect health care costs data for China, the health care costs for CHD calculated within 
this case study are limited to only the direct health care costs including outpatient and 
inpatient care costs.  
 
In order to simplify the calculation, the estimated cost of illness savings under trans 
fat-free vegetable oil substitution are limited to savings only from cardiovascular disease. 
Other possible health improvements from reduced consumption of TFA are not 
considered in this case study. Following Malla et al. (2007), a 1:1 ratio is assumed 
between reduced CHD risks and health-care cost savings for first three levels; thus, the 
related costs will be decreased by 1 percent if CHD is reduced by 1 percent. For the low 
level, it is assumed that for every percentage reduction in CHD, cost will only be reduced 
by half a percent (Malla et al., 2007). The calculation for health care savings concentrate 
solely on the expansion quantities in the market due to trade liberalization, a HCS rate (%) 
is introduced into the last step calculation ( For details, see section A3.2.1 in appendix 3). 
 
Table 4.5 Potential health care savings estimated in China  
 
 Base High Medium  Low 
TC change due to 1 g TFA reduction daily(%)
a
 1.55 1.55 1.55 1.55 
Daily TFA reduction (g) 0.40 0.99 0.79 0.20 
Total change in TC (%)
b
 0.62 1.53 1.22 0.31 
TC to CHD ratio
 c
 2.0 3.0 2.0 2.0 
Change in CHD (%)
d
 1.24 4.60 2.45 0.62 
Change in CHD (%) to change in cost (%)  1 : 1 1 : 1 1 : 1 1 : 0.5 
Total annual CHD cost($ million US dollars)
 e
 3850 3850 3850 3850 
Total change in annual CHD cost due to TFA 
reduction in daily diet 
($ million US dollars)
 f
 
48 177 94 12 
Health Care Savings (HCS) rate g 1.66% 1.65% 1.66% 1.66% 
Final HCS ($ million US dollars)
  h 0.79 2.92 1.56 0.20 
a Total Cholesterol (TC) change is rated at 1.55: 1 due to 1 g of TFA reduction. 
b Total change in TC (%) = TC change due to 1 g TFA reduction daily(%) * Daily TFA reduction (g) 
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c The relationship between total cholesterol and CHD is 1:2 based on Expert Panel (1988). For the 1:3 ratio is used for 
high level estimation which assumed to be the long-term ratio. (Source: Malla et al., 2007) 
d Change in CHD (%) = total change in TC (%) * TC to CHD ratio  
e Source: NCCD (2005).   
f Total change in CHD cost = total annual CHD cost * Change in CHD(%) * Change in CHD (%) to change in cost (%) 
ratio 
g See Section A3.2.1 in Appendix 3 for details.  
h HCS = Total change in annual CHD cost * HCS rate (%) 
 
In Table 4.5, the total change in annual CHD cost due to trans fat-free canola/rapeseed 
oil substitution is calculated. A range of scenarios are calculated given the incomplete 
nature of the data on HCS. These scenarios are based on Malla et al. (2007).  
 
The base case estimation assumes that 20 percent of the hydrogenated vegetable oils 
market is replaced by trans fat-free vegetable oils, leading to a 0.40g daily trans fat 
intake reduction in China. With the assumed 1:2 cholesterol to CHD risk ratio it provides 
a saving of about US $0.79 million in health-care and medical costs annually in China.  
 
The high level assumption is based on an optimistic perspective that trans fat-free 
vegetable oils cover a 50 percent market share in hydrogenated vegetable oils such as the 
shortening and the salad oil, accounting for a 0.99g trans fat intake reduction daily in 
China. With the assumption that every percentage change in total cholesterol leads to a 3 
percent change in CHD and 1:1 ratio between the incidence of CHD and the resulting 
costs to society, high level estimation results in a saving of about US $2.92 million in 
Chinese health care costs. 
 
For medium estimate, trans fat-free vegetable oil is assume to substitute 40 percent of the 
hydrogenated vegetable oils market, which together results in a 0.79g trans fat intake 
reduction daily in China. Given a smaller ratio with every percentage change in 
cholesterol level which lead to a 2 percent reduction in CHD, this results in a saving of 
about US $1.56 million in health care costs annually in China based on an assumed 1:1 
ratio between the incidence of CHD and the resulting costs to society.  
The low scenario demonstrates potential health-care cost savings under very conservative 
assumptions. Trans fat-free oils are assumed to reach only a 10 percent market share in 
the hydrogenated vegetable oils market. There is a 0.20g trans fat intake reduction daily 
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in China. Besides, a reduced ratio with 1:0.5 is applied between CHD change and 
health-care costs instead of the former 1:1 ratio. Although every step is extremely 
conservative, the low scenario still suggests a potential reduction of about US $0.2 
million in health-care and medical costs annually in China.  
 
4.4.2.3 Final Ratio Calculation 
Recall from Chapter 3, putting a tariff in place changes total welfare. If the objective of 
the protection policy was to increase producer surplus, decision makers must weigh the 
benefits of producers more heavily than benefits of consumers. According to the 
assumption made in Chapter 3, the ratio   will be applied here to give decision 
makers weighting of the changes in consumer surplus and producer surplus as well as the 
health cost savings arising from the imposition of a tariff on canola/rapeseed oil imports 
in China.  
 
Table 4.6 shows the calculations undertaken to derive the ratios used in the comparison. 
From the table, the ratios for canola/rapeseed oil are calculated based on the results from 
the previous sections. In summary, in the absence of the information pertaining to the 
health benefits from canola/rapeseed oil, 
M
=1.11. With the health benefits, this ratio 
rises to 1.33 in the base case, 1.67 in the high case, 1.56 in the medium case and 1.22 in 
the low case. Two conclusions can be made from final results. First, notice that both 
M
 
and  
N
 are larger than 1. That means, the loss for consumers arising from the higher 
price caused by tariff is larger than the gain by producers. The empirical study of China is 
consistent with the analysis in Case 1 of Chapter 3. The ratio shows a bias towards 
producers when policy makers in China framed their trade policy. Currently, canola and 
canola product imports face significant obstacles in China. Even if the tariff rate has been 
reduced from 19.9 percent due to WTO commitments, both canola oil and canola seed 
still face a tariff rate of 9 percent. The trade policy on canola/rapeseed oil imports is 
welfare reducing for the domestic economy. The tariff restriction on imports reduced 
consumer benefits from consumption of canola/rapeseed oil to a considerable degree. In 
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addition, canola and canola products face considerable discrimination as the Chinese 
tariff on canola and its products is 9 percent while there is only a 3 percent tariff on 
soybeans (Grain Growers of Canada, 2007). The current 6 percent difference in tariffs 
between soybeans and canola leads to additional losses for consumers due to the 
relatively higher prices caused by the limitation on imports of canola/rapeseed oil. Policy 
makers in China may wish to reconsider the trade policy related to canola/rapeseed oil 
imports given the new information on the ratio of losses versus benefits.. Reducing tariff 
levels on canola/rapeseed oil might be a better trade policy for China.  
 
Secondly, the result shows that  
N
 is larger than  
M
 at all four levels which is also 
consistent with the analysis from Case 1 in Chapter 3. Given the demand for 
canola/rapeseed oil, consumers suffer a greater loss due to the higher domestic price. 
Considering health benefits and health care cost savings on canola/rapeseed oil, the 
weighting ratio is considerably larger than before the health benefits of canola/rapeseed 
oil became known. At the base level with 20 percent TFA reduction in daily trans fat 
intake, the loss for consumers arising from the higher price is nearly one and a half times 
larger than the gain by producers. The high and medium levels even show over one and a 
half times weight given to producer benefits relative to consumer benefits. Though at the 
low level, consumers still lose more than the gain for producers. Therefore, from a 
welfare perspective, political decision makers may wish to re-evaluate their decisions on 
the import policy towards canola/rapeseed oil. 
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Table 4.6 Final ratio calculation 
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Chapter 5: United Kingdom (UK) Case Study 
This chapter provides a UK case study to examine the potential welfare benefits 
forgone from the existence of trade barriers when canola oil becomes a functional 
food. First, the chapter gives a brief introduction on the EU vegetable oils market. 
Further, the existence of trade barriers —  notable as GMO ban is discussed. 
Following this introduction, the empirical case study of UK‘s canola/rapeseed oil is 
examined according to Case 2 in the framework developed in Chapter 3.The forgone 
benefits of functional canola/rapeseed oil in UK arising from the trade barriers — a 
GMO ban – are calculated.  
 
5.1 The EU vegetable oils market 
In recent years, the vegetable oil market in the EU has changed dramatically and is 
now strongly driven by the demand for biodiesel. As a result, there is competition 
between vegetable oil used as an input to biodiesel and for human consumption 
(Bendz, 2007). Across the whole range of oils and fats, approximately 80 percent is 
used as human food, a further 6 percent is an input to animal feed and the balance (14 
percent) provides the raw material for the oleochemical (bio-fuels, solvents) industry 
(Gunstone, 2001).  
 
Rapeseed oil has become the primary feedstock for biodiesel in Europe. Government 
mandated bio-diesel production led to rapeseed oil consumption across the EU 
increasing by 20 percent in 2004-2005. By 2006, approximate 60 percent of the total 
rapeseed oil produced in the EU was used to provide biodiesel (Ho, 2006). The major 
producing countries are Germany, France, the UK and Poland (Profarmer, n.d.). In the 
UK, rapeseed oil represents about 33 percent of total oil and fat output (Gunstone, 
2001).The area planted to rapeseed in the UK has been steadily increasing and 
is estimated to continue to increase by over 20 percent year by year in the near term 
(Bendz, 2007).  
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Prices of rapeseed and rapeseed oil have been strong due to rising demand 
for rapeseed from both the biodiesel and food industries. Strong demand for bio-fuels, 
however, has led to a considerable decline in imports of rapeseed and canola 
oil moving into food supply chains (Bendz, 2007). The price of rapeseed oil across the 
EU rose by 45 percent in 2005, and then an additional 30 percent to about US$800 per 
tonne in 2006 (Ho, 2006).  
 
5.2 GMO ban 
While the domestic market is expanding rapidly, the import market for rapeseed oil is 
heavily constrained. The EU has had community-wide legislation on genetically 
modified organisms (GMOs) since 1998. Before being placed on the market, GMOs 
must first undergo a very strict assessment process. If approved, they must be labeled 
and managed in accordance with strict product traceability requirements (EUROPA, 
n.d.). The majority of products that use genetic modification technology in their 
production, especially imported products, could not enter into the market because of a 
stringent science-based assessment and a lengthy approval process. GMOs are a 
contentious political issue in the EU which delayed the establishment of an 
expeditious approval mechanism and continues to inhibit approvals (Phillips, 2006).  
 
Europeans preferred the name oilseed rape, rape oil, or rapeseed oil to the name 
canola. One unique difference, however, is that Europe does not permit the making of 
canola oil from genetically modified plants (VitaminsDiary, n.d.). European farmers 
are prevented by law from growing genetically modified rapeseed. However, over the 
period since 1995 about 80 percent of the canola grown in Canada has now been 
modified using biotechnology to make it tolerant to some herbicides (Canola Council 
of Canada, 2008f). Thus, Canadian canola is currently banned from the European 
food market as the GM varieties of canola have not been approved for import into the 
EU and there is no segregation of GM and non-GM canola in the post-harvest supply 
chain (Smyth et al., 2006).  
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In the past, Australia has been an important supplier of canola to the EU market. 
Canola is now Australia‘s third largest broad-acre crop just after wheat and barley 
(AOF, n.d.). Australia is viewed as the major non-GM canola products exporting 
country for Europe. The non-GM attribute provides a marketing advantage for 
Australian canola products in the EU market. On the one hand, however, Australia 
exports canola primarily in seed form, with only small quantities of oil exports and 
virtually no canola meal exports (Foster and French, 2007). On the other hand, 
Australian canola exporters have not been able to consistently capture non-GM 
premiums because the EU is an inconsistent market for Australian canola (AOF, 
2003). The import trade of canola products from Australia has been considerably 
influenced by weather conditions in the EU. Large imports are required only when 
adverse weather conditions affected the EU rapeseed harvest (see Table 5.1).  
 
Table 5.1 EU rapeseed products imports from Australia 
 
 
2000 
(Kt)
 a 
2001 
(Kt) 
2002 
(Kt) 
2003 
(Kt) 
2004 
(Kt) 
2005 
(Kt) 
2006 
(Kt) 
Australia 
(mainly in 
rapeseed) 
0 362 63 1 94 0 287 
a 1 Kt = 1000 tonne. 
Sources: United Nations Statistics Division (2006). 
 
Due to potentially large export markets for GM products outside the EU, in 2003, 
Australia's gene technology regulator approved the release of canola that had been 
genetic modified to resist the herbicide Glufosinate ammonium (Sydney Morning 
Herald, 2003). There appears to be a rapid shift to the growing of GM varieties of 
canola in Australia.  
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In the face of pressure from major GM grain exporting countries, the EU has made 
some concessions on the imports of GM products. In late 2004, some GM grain 
varieties were approved but imports of the most important varieties of GM canola are 
still not allowed (Foster and French, 2007). In 2006, the European Commission 
announced that three oilseed rapes known as Ms8, Rf3 and Ms8xRf3 that are 
genetically modified for tolerance to the herbicide glufosinate-ammonium are 
authorized to be placed on the EU market. These oilseed rapes are allowed to be 
imported but only for processing into animal feed or for industrial purposes not for 
cultivation (EUROPA, 2007). They cannot be imported if destined for the human food 
supply channel. Thus, the EU market including the UK is effectively closed to canola 
imports that can enhance human health. 
 
5.3 Modelling the UK rapeseed oil market 
Recall from the model developed in Chapter 3, Case 2, where both domestic 
producers and international sources of supply are assumed for a new functional food. 
In Case 2, the new functional food faces a regulatory trade barrier that is equivalent to 
an import ban. Therefore, canola oil that suffers from a GMO import ban which 
prevents market access to the U.K is a suitable example for a case study under the 
assumptions contained in Case 2
28
. 
 
The European Union is a major producer of rapeseed. In the past, it has been a net 
exporter of rapeseed products. The EU‘s net exports have declined in recent years and 
the EU is now becoming a net importer of both rapeseed and rapeseed oil due to 
strong demand as an input to biodiesel production (Foster and French, 2007). For 
example, the EU increased its imports of rapeseed oil from 38 Kt to 335 Kt in 2006 
(see Table 5.2). However, the increased imports of rapeseed and rapeseed oil are still 
small relative compared to the large domestic production — approximately 5 percent 
of domestic production in 2006 (see Table 5.2). Further, the EU has diverted more 
                                                 
28 The assumption being made is that any small remaining quantities of non-GM imports of canola provided from 
Australia can be safely ignored.  
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than three million tonnes, or 60 percent, of its rapeseed oil production to biodiesel 
production (Business Times, 2008). More than half of the imports went to biodiesel 
production in order to satisfy mandated increased utilization of this new transport fuel. 
Thus, the remaining imports of rapeseed oil for food use from other countries only 
cover a tiny portion of the domestic market for rapeseed oil consumption. Thus, it is 
assumed for the purpose of this case study that the EU, and hence the UK, are closed 
to cheaper international sources of canola oil. 
 
 Table 5.2 EU - supply and disposal of rapeseed oil (Kt) 
 
Source: US Department of Agriculture (2006). 
 
With its trans fat-free health enhancing attributes, it is assumed that canola/rapeseed 
oil as a functional food will have increased in popularity in the EU market if 
consumers have access to the functional product. However, since the EU has 
established very strict laws governing the import of GM canola, opportunities in 
promoting health benefits may be lost while GM canola imports are prohibited. 
Hence, in the UK case study, imports of rapeseed oil from countries outside the EU 
are assumed to be to be zero in order to better capture the foregone benefits arising 
from the GMO ban.  
 2002-2003 2003-2004 2004-2005 2005-2006 
Opening 
Stocks 
320 315 152 200 
Production 4353 4339 5365 5945 
Imports 7 33 38 335 
Total supply 4680 4687 5555 6480 
Domestic 
Consumption  
4115 4392 5365 5945 
Exports 250 143 125 75 
Closing stocks 315 152 200 190 
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5.4 Case calculation  
5.4.1 Trade effects calculation 
Recall from Case 2 in Chapter 3, reproduced in Figure 5.1, D
M
 is the demand curve of 
canola/rapeseed oil in the UK market prior to the health improvement benefits 
becoming apparent. There is also a supply curve S
M 
for canola/rapeseed oil. At Pw, 
the world price for canola/rapeseed oil, consumers are willing to purchase Q
DM 
and 
domestic producers will only supply Q
SM
. Imports would be (Q
DM
- Q
SM 
). However, 
there is a GMO ban in the UK imposed on the import of canola/rapeseed oil. 
Therefore, it raises the price to P
E
M and the quantity consumed will be Q
EM
.
29
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* For calculation purposes, a5 is divided into a5a and a5b .a3 is divided into a3a and a3b. 
Figure 5.1 Case 2 — domestic and import supply, 
 trade prohibiting regulation in the UK 
                                                 
29 Note we are assuming that the SM curve includes any transfers within the EU‘s single market.  
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Without the GMO import ban, the consumer surplus is area a1 +a2 + a5 + a6+ a7 + a8. 
Producer surplus is area a9
30
. After the GMO import ban is implemented, consumer 
surplus decreases to area a1 +a2 with a reduction of a5 + a6+ a7 + a8. Producer surplus 
increases to area a5 +a9 with an increase equal to area a5. 
 
As in the Chinese case study presented in Chapter 4, canola/rapeseed oil can also be 
seen as a functional food in the current food market in the UK. As we assumed in the 
Case 2, more people are willing to buy canola/rapeseed oil given its newly recognized 
health enhancing attributes — only recognized after the GM import ban was put in 
place. In addition, consumers are willing to pay at least the same price or a premium 
for higher quality (health enhancing) canola/rapeseed oil. Therefore, the increased 
consumption of new health enhancing canola/rapeseed oil shifts the demand curve out 
to D
N 
. Faced with the same world price at Pw, the consumer surplus increases to area 
a1 +a2 + a3 + a4 + a5 + a6 + a7 + a8 + a10 + a11. As the world price is unchanged and the 
supply curve is not altered, domestic producer surplus remain equal to area a9.   
 
With the import ban in place, however, no import of canola/rapeseed oil exists in the 
domestic market in the UK. Hence, the domestic price P
E
M rises to P
E
N and the 
quantity consumed equals Q
EN
 with the increased demand. With higher price P
E
N, 
consumer surplus decreases to area a1 +a10. Consumers suffer a loss of area a2 + a3 + 
a4 + a5 + a6 + a7 + a8 + a11 in consumer surplus because of the higher price. On the 
other hand, new producer surplus increases to area a2 +a3+ a5 +a9 — a change equal to 
a2 +a3+ a5. 
 
Thus, before new health information on canola/rapeseed oil was received, the trade 
changes are areas a5 + a6 + a7 + a8 — the decrease in consumer surplus and a5 — the 
increase in producers surplus. Both a5 + a6 + a7 + a8 and a5 are trapezoid areas that can 
                                                 
30 Given that SM includes within EU transfers, the estimates of producer surplus may exceed the value of producer 
surplus that accrues to British producers.  
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be divided into rectangles and triangles for the calculation of their values
31
. After the 
health enhancing attributes of canola/rapeseed oil having been recognized by the 
consumers, the trade change is area a2 + a3 + a4 + a5 + a6 + a7 + a8 + a11 in consumer 
surplus and a2 +a3+ a5 in producer surplus. Area a2 + a3 + a4 + a5 + a6 + a7 + a8 + 
a11can be divided into rectangle a2 + a3 + a4 + a5 + a6 + a7 and triangle a8 + a11. Area a2 
+a3 can be divided as rectangle a2 +a3a and triangle a3b. Combined with the data from 
Table 5.3, the calculations and resultant values can be found in Table 5.5. 
 
Table 5.3 Market data of canola/rapeseed oil in the UK (2006)
 a 
 
Total domestic consumption/supply (Mt) – QEN b 0.63 c 
Supply elasticity - 
S   0.84 
d 
Demand elasticity - 
D  -0.50
 e 
Average world price($ US dollars/tonne) - Pw 553 
f 
Current domestic price($ US dollars/tonne) – PN
E  
 983
 g
 
Domestic demand (Mt) without GMOs ban- Q
DN
 0.77 
h
 
Domestic supply (Mt) without GMOs ban - Q
SM
 0.40 
i 
Demand increasing rate
 j
 Base 30%
 
High 50% 
Medium 40% 
Low 20% 
Original domestic consumption (Mt) at PM
E
 - Q
EM
 
k
  Base 0.48 
High 0.42 
Medium 0.45 
Low 0.525 
Original price before demand shifts– PM
E 
($ US dollar/tonne)
 l
 
Base 704 
High 593 
                                                 
31 Assuming, of course, linear supply and demand curves. 
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Medium 649 
Low 788 
domestic consumption (Mt) at Pw - Q
DM  m
 Base 0.53
 
High 0.43 
Medium 0.48 
Low 0.60 
a All the data period is based on year 2006.  
b Different from the Chinese case study in the chapter 4, rapeseed oil has been well-known for its trans fat-free and 
other health enhancing benefits in the UK market for over 10 years. Thus, it is assumed that the total domestic 
consumption/supply of rapeseed oil is QEN. That means the demand curve DM has already been shifted to DN in the 
current market. The initial price for the purpose of calculation is, hence, PN
E. 
c Source: FEDIOL(2006).  
d Note: it is a oilseed area response elasticity for oilseed oil supply. (Source: Meilke et al, 2001)   
e Note: it is a direct price elasticity for oilseed oil demand. (Source: Meilke et al, 2001) See  
f Average Pw is based on period from 87/88 to 05/06. Source: USDA (1999) and USDA (2008).  
g Raw vegetable oil price in Netherlands and Germany. Source: Horváth, 2006. 
(Origin: 162,663 HUF. Convert to US $ 982 based on 1:0.006042 (HUF: USD) currency rate. Source: Yahoo 
Finance, Sept 27th , 2008.)   
h QDN is calculated from the following steps using demand elasticity: 
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= 0.77 (Mt) 
i QSM is calculated from following steps using supply elasticity: 
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= 0.4 (Mt) 
j. Demand increases are estimated from current reports and studies regarding to the UK‘s functional food market. 
For details, see Appendix 2.2.  
k QEM  = QEN/ (1+Demand increasing rate)  
l PM
E is calculated from following steps using supply elasticity: 
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Similar to China‘s case study, much of the data used in the UK case study calculations 
are derived from previously published sources including the demand and supply 
elasticities used. The elasticity of demand and supply in the UK case study were 
obtained also from Meilke et al. (2001). Since both the elasticity of demand and 
supply are derived from previously published studies, there is a need to check the 
robustness of the results in the case studies. Hence, a sensitivity analysis is conducted 
at both higher and lower levels. Table 5.4 shows the trade effects ratio under different 
elasticity values in the UK case study. 
 
Table 5.4 Sensitivity analysis for elasticity in the UK case study 
 
 
In the sensitivity analysis for elasticities in the UK Case study, the final ratio 
M
 is 
0.02 larger and 0.01 smaller than its original value. The impact of elasticity values on 
the trade effect, is small approximately 2 percent. Since the elasticity values in the UK 
case study are larger than they are in Chinese case study, the 2 percent changes is also 
 D  QDM (Mt) S  QSM (Mt) 
M
 
Original 
level 
-0.50 0.67 0.84 0.56 1.09 
Higher level
（+20%） 
-0.60 0.68 1 0.55 1.11 
Lower level 
(-20%) 
-0.40 0.66 0.67 0.57 1.08 
 73 
an acceptable result indicating that the trade effects ratio is not particularly sensitive 
to the different elasticity values. Therefore, the original combination of demand and 
supply elasticities can still be used in the UK case study without any particular 
concerns.  
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Table 5.5 Trade effects calculation in the UK case study  
 
a5 + a6 + a7 + a8 a5 a2 + a3 + a5 a2 + a3 + a4 + a5 + a6 + a7 + a8 + a11 
 Rectangl
e 
a5 + a6 
Triangle 
a7 + a8 
  
Rectangle 
a5a 
Triangle 
a5b 
Rectangle 
a2 + a3a 
Triangle 
a3b 
a5 
Rectangle 
a2 + a3 + a4 + 
a5 + a6 + a7 
Triangle 
a8 + a11 
Formula 
Q
EM‘
* 
(PM
E
 
-PW) 
1/2*( Q
DM
 
– QEM)* 
(PM
E
 -PW) 
Q
SM
 *  
(PM
E
 
-PW) 
1/2*( Q
EM
 
– QSM)* 
(PM
E
 -PW) 
Q
EM
 * 
(PN
E
 – PM
E
 ) 
1/2*( Q
EN
 
– QEM)* 
(PN
E
 - 
PM
E
 ) 
 
Q
EN
 *  
(PN
E
 -PW) 
1/2*( Q
DN
 – QEN)* 
(PN
E
 -PW) 
Result 
(Million$) 
High 16.8 0.2 16 0.4 163.8 40.95 16.4 
270.9 30.1 
Med 43.2 1.44 38.4 2.4 150.3 30.06 40.8 
Base 72.48 3.78 60.4 6.04 133.92 20.93 66.44 
Low 123.38 9.4 94 14.69 102.38 10.24 108.69 
High 
17 16.4 221.15 
301 
Med 
44.64 40.8 221.16 
Base 
76.26 66.44 221.29 
Low 
132.78 108.69 221.31 
 
7
4
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Table 5.5 shows all the calculations and results for the trade effects of canola/rapeseed 
oil. According to the above table, with a GMO ban on imports of canola/rapeseed oil 
in the UK, consumers suffer a loss from US$17 million to US$133 million at four 
different levels for consumer surplus change (area a5 + a6 + a7 + a8) because of the 
higher domestic price. On the other hand, producers gain US$16.4 million to 
US$108.7 million at four different levels in producer surplus change (area a5). Results 
showed that consumer loss at every level is more than producer gain. However, after 
health information regarding canola/rapeseed oil become well-known to the public, 
consumers‘ loss increases relative to producers‘ gain. A US$301 million loss in 
consumer surplus (area a2 + a3 + a4 + a5 + a6 + a7 + a8 + a11) has been calculated in 
Table 5.5. Without sufficient imports, increased consumption of canola/rapeseed oil 
raised the domestic market price leading to the loss in consumer surplus. This loss is 
increased substantially compared to former loss in consumer surplus at the four 
different levels. Even at base levels with the US$221 million gain in producer surplus, 
the increased consumption of healthy canola/rapeseed oil leads to more loss in 
consumer surplus than when the health benefit was unknown. Although the producer 
surplus also increased (area a2 + a3 + a5), the comparative increase is less than the 
decline in consumer surplus. As expected, the results of trade effects indicate that the 
import ban generates a larger loss in consumer welfare than the gain on the producer 
side and it is even larger after the shift in demand for canola/rapeseed oil arising from 
its health attributes becoming known.  
 
5.4.2 Estimating the potential health care cost savings for the UK 
case study 
Following a similar methodology to that used in section 4.3.2.2 for the Chinese Case 
study, the model developed by Malla et al. (2007) is adapted to estimate the potential 
health benefit and related medical cost savings arising from the consumption of more 
healthy trans fat-free canola/rapeseed oil in the UK. 
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Step 1: Estimate possible daily trans fat intake reduction due to ‗trans fat-free canola 
oil in the UK 
In step 1, a total trans fat consumption (intake) per day is estimated using available 
studies. Hulshof et al. (1999) studied the intake of fatty acids in Western Europe. 
They found that in the United Kingdom, the main sources of TFA were partially 
hydrogenated oils and fats which contribute 35 percent of the intake of total trans 
fatty acids in the diet. Of these, margarines, spreads, frying and cooking fats and oils 
contributed at least 31 percent TFA in the diet. The study further revealed that a total  
daily intake of individual trans fatty acids among 11 fatty acid isomers from selected 
food sources per day is 40.92g in the UK.
32
 
 
From Table 5.6, the effect of trans fat-free canola oil substitution can be seen. Using 
sensitivity analysis, the estimation assumes four level of substitution from base (20%), 
high (50%), medium (40%) and low (10%). The resulting reductions in trans fat 
consumption are 0.89 g (Base), 2.22g (High), 1.78 g (Medium) and 0.44 g (Low)  
daily in the UK.  
 
 
 
 
 
 
 
 
 
 
                                                 
32 11 fatty acid isomers are C14 :1t9 (0.11 g methylesters/day), C16 :1t9 (0.18 g methylesters/day), C18 :1t (2.00 g 
methylesters/day), C18:2t (0.28g methylesters/day), C18:3t+C20:1 (0.17g methylesters/day), C20:2t11,14 (0.02 g 
methylesters/day), C22:1t (0.06 g methylesters/day), C18:1c9 (19.3 g methylesters/day), C18:2c9,12 (11.4 g 
methylesters/day), C18 :3c9,12,15 (1.4 g methylesters/day), C18:0 (6.0 g methylesters/day).  
Source: Hulshof et al. (1999). 
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Table 5.6 Trans fatty intake reduction in the UK due to trans-fat-free canola oil 
a Source: Hulshof et al. (1999). 
b According to Hulshof et al. (1999), the main sources of TFA were partially hydrogenated oils and fats which 
contribute 35 percent of the intake of total trans fatty acids in the diet. Of these, margarines, spreads, frying and 
cooking fats and oils contributed at least 31 percent TFA in the diet. Thus, a contribution rate is applied to reveal 
total TFA intake due to hydrogenated oils consumptions. Contribution rate (%) is calculated from the product of 
35% times 31%. 
c TFA intake due to hydrogenated oils consumptions = Contribution rate * total TFA (intake) per day 
d TFA reduction (%) in sample foods is assumed have four levels from base, high, medium to low. These four 
levels indicates the percentage of vegetable oils found in daily food consumption that is assumed to be substituted 
by trans fat-free canola oil. The TFA reduction ratio guarantees the subsequent calculations focus solely on the 
health care cost savings for a certain group of people who consumed trans fat-free canola/rapeseed oil rather than 
other vegetable oils. 
e The total TFA reduction = The Total TFA intake daily (g) * Assume TFA reduction (%) 
 
Step 2: Calculate cholesterol change (LDL & HDL) due to reduced trans fat 
consumption 
According to Malla et al. (2007), a number of studies have measured the effects of 
TFA consumption on LDL, HDL, and total cholesterol levels using controlled diets. 
Following Malla‘s conclusion, in step 2, the assumption is made that for every 1 g 
reduction in TFA, total cholesterol will reduced by 1.55 percent. 
 
Step 3: Calculate CHD risk reduction due to changes in cholesterol profile 
 base High medium Low 
Total daily TFA (intake) per person (g)
 a
 40.92 40.92 40.92 40.92 
Contribution rate (%)
 b
 10.85 10.85 10.85 10.85 
TFA intake due to hydrogenated oils 
consumption 
c
 
4.44 4.44 4.44 4.44 
Assume TFA reduction (%)
 d
 20 50 40 10 
Total TFA reduction (g)
 e
 0.89 2.22 1.78 0.44 
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Drawing on the conclusions of the US National Cholesterol Education‘s Expert Panel 
(Expert Panel, 1988), the assumption can be made that there is a 2% reduction in the 
risk of CHD for every 1 percent reduction in cholesterol levels for the medium, base 
and low cases, while for the high level a 3 percent reduction in CHD risk is assumed 
(Malla et al., 2007).  
 
 
Step 4: Calculate cost changes from reduced incidence of CHD 
The final step in the analysis (step 4) is to calculate the potential health-care cost 
savings from trans fat-free canola oil in the UK.  
 
Each year cardiovascular disease causes over 4.3 million deaths in Europe and over 
2.0 million deaths in the European Union which accounts for nearly half of all deaths 
(Allender et al., 2008a). Cardiovascular disease (CVD) leads to larger economic and 
human costs for Europe. From European cardiovascular disease statistics provided by 
European Heart Network, CVD costs the health systems of the EU about € 110 billion 
(US$172.7 billion)
33
 in 2006 which represents around 10% of the total health care 
expenditure across the EU (Allender et al., 2008a). Further, production losses from 
CVD deaths and illness are also considered into the overall CVD costs leading to a 
cost of € 192 billion (US$301.44 billion) a year. CHD accounts for one-quarter of 
these overall costs (Allender et al., 2008a). In the United Kingdom, the total costs of 
CHD are approximate £9.0 billion (US$17.82 billon)
34
 in 2006. Of the total cost of 
CHD to the UK, around 36% is due to direct health care cost, 43% to productivity 
losses, and 21% to the informal care of people with CHD (Allender et al., 2008b).  
 
In order to simplify the calculation, the estimated cost of illness savings under trans 
fat-free vegetable oil substitution are limited to savings only from cardiovascular 
disease. Any other possible health improvements from reduced consumption of TFA 
                                                 
33 I use EUR: USD = 1:1.57, based on the current market foreign exchange rate (2:00pm, July 7, 2008).  
34 I use GBP: USD = 1:1.98, based on the current market foreign exchange rate (average, July 7, 2008). 
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are not considered in this study. Following Malla et al. (2007), a 1:1 ratio is assumed 
between reduced CHD risks and health-care cost savings for the first three levels; thus, 
the related costs will be decreased by 1 percent if CHD is reduced by 1 percent. For 
the low level, it is assumed that for every percentage reduction in CHD, cost will only 
be reduced by half a percent (Malla et al., 2007). The health care savings are limited 
to the opportunities for increased consumption arising from trade liberalization, a 
HCS rate (%) is introduced into the last calculation step ( For details, see section 
A3.2.2 in appendix 3). 
 
Table 5.7 potential annual health-care savings estimated in the U.K 
 
 Base High Medium Low 
TC change due to 1 g TFA reduction 
daily (%)
a
 
-1.55 -1.55 -1.55 -1.55 
Daily TFA reduction 0.89 2.22 1.78 0.44 
Total change in TC (%)
b
 1.38 3.44 2.76 0.68 
TC to CHD ratio 
c
 2.0 3.0 2.0 2.0 
Change in CHD (%)
d
 2.76 10.32 5.52 1.36 
CHD to cost ratio 1.0 1.0 1.0 0.5 
Total annual CHD cost  
(million U.S dollars)
 e
 
17820 17820 17820 17820 
Total change in annual CHD cost due to 
TFA reduction in daily diet  
(million US dollars)
 f
 
492 1839 984 121 
Health Care Savings (HCS) rate g        22% 22% 22% 22% 
Final HCS (million US dollars)
 h 108.24 404.58 216.48 26.62 
a Total Cholesterol (TC) change is rated at 1.55: 1 due to 1 g of TFA reduction. 
b Total change in TC (%) = TC change due to 1 g TFA reduction daily(%) * Daily TFA reduction (g) 
c The relationship between total cholesterol and CHD is 1:2 based on Expert Panel (1988). For the 1:3 ratio is used 
for high level estimation which assumed to be the long-term ratio. (Source: Malla et al., 2007) 
d Change in CHD (%) = total change in TC (%) * TC to CHD ratio  
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e Source: Allender et al., (2008b).  
f Total change in CHD cost = total annual CHD cost * Change in CHD(%) * Change in CHD (%) to change in cost 
(%) ratio 
g See Section A3.2.2 in Appendix 3 for details.  
h HCS = Total change in annual CHD cost * HCS rate (%) 
 
In Table 5.7, the total estimated change in annual CHD cost in the UK due to trans 
fat-free canola/rapeseed oil substitution is calculated. A range of scenarios are 
calculated given the incomplete nature of the data on HCS based on Malla et 
al.(2007).  
 
The base estimation assumes that 20 percent of the hydrogenated vegetable oils 
market are replaced by trans fat-free vegetable oils, leading to a 0.40g trans fat intake 
reduction daily in the UK. With the assumed 1:2 cholesterol to CHD risk ratio a 
saving of US$108 million in health-care costs is generated annually in the UK.  
 
The high level assumption is based on an optimistic perspective that trans fat-free 
vegetable oils cover a 50 percent market share in hydrogenated vegetable oils such as 
the shortening and the salad oil, accounting for a 0.99g trans fat intake reduction daily 
in the UK. With the assumption that every percentage change in total cholesterol leads 
to a 3 percent change in CHD and 1:1 ratio between the incidence of CHD and the 
resulting costs to society, the high level estimation results in a saving of US$405 
million in the UK medical costs annually. 
 
For the Medium estimate, trans fat-free vegetable oil is assume to substitute for 40 
percent of the hydrogenated vegetable oils market, which together results in a 0.79g  
daily trans fat intake reduction individually in the UK. Given that a smaller ratio with 
every percentage change in cholesterol level which leads to a 2 percent reduction in 
CHD, this results in a saving of US$216 million in health-care costs annually in the 
UK based on an assumed 1:1 ratio between the incidence of CHD and the resulting 
costs to society.  
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The low scenario demonstrates potential health-care cost savings under very 
conservative assumptions. Trans fat-free oils are assumed to reach only a 10 percent 
market share in the hydrogenated vegetable oils market. There is a 0.20g trans fat 
intake reduction daily in the UK. Further, a reduced ratio of 1:0.5 is applied between 
CHD change and health-care costs instead of the former 1:1 correlation. Although 
every step is extremely conservative, the extreme low scenario still suggests a 
potential reduction of US$27 million in health-care costs annually in the UK.  
 
5.4.3 Final ratio calculation 
Following the method in section 4.3.2.3 for the China‘s case study, the ratio   will 
also be applied here to derive the decision makers‘ weighting of the changes in 
consumer surplus and producer surplus as well as the health cost savings arising from 
the imposition of an import ban on canola/rapeseed oil import in the UK.  
 
Table 5.8 shows the calculations undertaken to derive the ratios used in the 
comparison. From the table, the ratios for canola/rapeseed oil are calculated based on 
the results from the previous sections. In summary, in the absence of the information 
pertaining to the health benefits from canola/rapeseed oil 
M
 is equal to 1.19 in the 
base case, 1.05 in the high case, 1.11 in the medium case to 1.26 in the low case. With 
the health benefits, this ratio rises to 1.78 in the base case, 2.32 in the high case, 2.0 in 
the medium case to 1.65 in the low case. Hence, two conclusions can be drawn from 
the final results.  
 
First, as predicted in chapter 3, both 
M
 and  
N
 are larger than 1. That means the 
loss for consumers arising from the higher price caused by tariff is larger than the gain 
to producers. The ratio indicates a preference for producer benefits over consumer 
benefits when policy makers frame trade policy for the UK within the EU. Currently, 
GM canola and canola product imports are strictly restricted in the EU , and hence 
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also the UK. Even if the import ban on GM canola and its product has been removed 
for certain types of GM products, most types of GM canola oil and canola seed still 
face a complete import ban. The ban on GMO imports largely reduced consumer 
benefits arising from the consumption of canola/rapeseed oil because of a higher price 
in the domestic market. The trade policy on canola/rapeseed oil import turns out to be 
welfare reducing for the domestic economy. Thus, policy makers in the EU and UK 
might wish to review their trade policy towards canola/rapeseed oil imports and push 
for removal of the import ban in the EU given the results for the ratio of losses versus 
benefits.  
 
Secondly, the result shows that  
N
 is much larger than  
M
 at all four levels, which 
is also consistent with the analysis from Case 2 in Chapter 3. Given the increased 
demand for canola/rapeseed oil in the UK market, consumers suffer a significant loss 
due to the higher domestic price caused by the import ban. Adding forgone health 
benefits and health care cost savings on canola/rapeseed oil into the ratio, the 
weighting ratio is considerably larger than before the health benefits of 
canola/rapeseed oil became known. At the high level with 20 percent TFA reduction 
in daily trans fat intake, the loss for consumers arising from the 30 percent increased 
demand is more than two times larger than the gain by producers. The high and 
medium levels even show around three times weighting being given to producer 
benefits relative to consumer benefits. At the low level, consumers still lose more than 
one and a half times the gain for producers. Therefore, from a welfare perspective, it 
is possible political decision makers may wish to re-consider their decisions on the 
import policy towards canola/rapeseed oil in the EU (and the UK) — and hence to 
push for reform in the EU.  
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Table 5.8  Final ratio calculation in the U.K case study 
 
   
Formula 
5
8765
M
 )      (
surplusproducer 
 surplusconsumer  
 
a
aaaa 




 
532
118765432
N
   
 HCS  )           (
surplusproducer 
HCS  surplusconsumer  
 
aaa
aaaaaaaa






 
Base 
76.26/64.17 
02.219
24.10861.348 
 
1.19 2.09 
High 
18/17.1 
216
58.40461.348 
 
1.05 3.49 
Medium 
44.44/39.87 
22.215
48.21661.348 
 
1.11 2.63 
Low 
132.78/105.16 
78.217
62.2661.348 
 
1.26 1.72 
 
 
 
 
 
 
 
 
 
 
 
 
N
 
M

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Chapter 6: Summary and conclusions 
 
6.1 Summary 
Innovation in food technology, along with increased interest in foods which provide 
health enhancing attributes beyond normal nutritional benefits, has led to the rapid 
development of the functional food industry. Functional foods provide positive 
externality benefits to society through the promotion of health benefits that reduce the 
opportunity cost of illness and lower the health care costs that are borne by 
governments. With strong market growth and considerable potential social benefits, 
functional foods appear to be an important area for future expansion in the global food 
market. However, the pre-existing trade barriers (i.e. those put in place before the 
positive health benefits became apparent) to international commence reduce, or 
sometimes eliminate, trade in functional foods. As a result, the benefits associated 
with health-giving attributes are forgone. The relationship between trade barriers and 
functional food is particularly important because the impact of trade policy may 
directly result in social costs and unrealized direct consumer benefits.   
 
Given that there may be additional benefits forgone from the existence of trade 
barriers, this thesis explored the potential welfare benefits foregone in importing 
countries from the existence of trade barriers when a traditional food becomes a 
―functional food‖. A theoretical trade model is developed with four cases illustrating 
the range of trade restrictions that may be applied in the case of functional foods. Case 
studies are then developed in the thesis to give an insight into the size of the benefits 
as well as to explore the limitations of conducting empirical estimations. 
Canola/rapeseed oil with functional attributes was selected as the functional food to 
use for the case studies. By examining the Chinese and the UK markets which have 
different trade restrictions for canola/rapeseed oil, the value of additional forgone 
benefits from existing trade barriers were estimated. These case studies are 
representative of two of the four theoretical models developed in the thesis. 
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The primary conclusions are drawn from the result of the case studies. Under a 
variety of assumptions and using calculation methods from health economics, this 
thesis has shown that the forgone benefits from healthier trans fat-free 
canola/rapeseed oils may be important. The change in the weighting of consumer to 
producer benefits, , is used to summarize the results. The post change ratio also 
includes health cost reductions. 
 
Table 6.1 Final ratio results from case studies 
 
 
        a     b
 Increasing %
  c
 
 
Chinese case 
 
Base 1.11 1.33 19.8% 
High 1.11 1.67 50.5% 
Medium 1.11 1.56 40.5% 
Low 1.11 1.22 9.9% 
UK case 
(direct & 
indirect HCS)
 d
 
Base 1.19 2.09 75.6% 
High 1.05 3.49 232.4% 
Medium 1.11 2.63 136.9% 
Low 1.26 1.72 36.5% 
UK case 
(direct HCS)
 e
 
Base 1.19 1.77 48.7% 
High 1.05 2.28 117.1% 
Medium 1.11 1.98 78.4% 
Low  1.26 1.64 30.2% 
a Final ratio before canola/rapeseed oil recognized as functional food. 
b Final ratio after canola/rapeseed oil recognized as functional food. 
c 
M
MN

   
 
N
 
M

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d  Results are from the calculations in the UK case study in chapter 5. The second step calculations for potential 
HCS estimate in the UK are based on both direct health care cost and indirect health care cost.    
e Results are from the calculations in the adjusted UK case study in Appendix 4. The second step calculations for 
potential HCS estimate in the UK are based solely on direct health care cost. The purpose for adjusting the ratio is 
to compare the forgone benefits between two case studies on a same basis with only direct health cost calculated 
into models. For details, see Appendix 4. 
 
The results in the Table 6.1 show that there appear to be important forgone benefits 
from existing trade barriers in the canola/rapeseed oil market. Considering health 
benefits and health care cost savings for canola/rapeseed oil, the positive increasing 
rate showed that the forgone benefits from trade barriers increased when comparing 
the final ratio to that which existed before canola/rapeseed oil was recognized as 
functional food. In the UK case study, the increasing rates are greater than those in the 
Chinese case study because the trade barrier in the UK market is more restricting — 
an import ban rather than a tariff. In other words, forgone benefits increase when 
more constringent trade regulations are faced. Even with adjusted ratio in the UK case 
study, the increasing rates are also greater at all four levels than those in the Chinese 
case study. Hence, the results are consistent with the predictions from economic 
theory. 
 
All of the results suggest that current trade regulations towards functional foods might 
be re-evaluated by policy makers. Existing trade policies may leave an imbalance 
between the gain from protection received by producers and the losses of consumers 
and society. Hence, policy makers may wish to reconsider past trade policy decisions 
in order to better reflect the evolving markets for functional foods. 
 
 
6.2 Limitation of the research 
There are a number of limitations to the work undertaken in this thesis that should be 
acknowledged. First, the data and elasticities used for calculation in the case studies 
are limited in the current available literature. The elasticities used in the trade effect 
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calculation are only rough approximations for the supply and demand of 
canola/rapeseed oil. The trans fat consumption data in China was calculated from a 
regional report – Hong Kong - rather than broad based research on diets in China. 
Indirect health care cost data for China is unavailable in the current literature, hence 
the final weighting ratio in the Chinese case study underestimates the true cost.  
 
Furthermore, the assumptions used in the case studies have been made based on 
limited information. As the consumer response to canola oil being recognized as 
having health enhancing properties has not been estimated, the magnitudes of the 
relative shifts in the demand curves are not directly available. Thus the demand shifts 
presented in the case studies were assumed based on the relevant studies of functional 
foods generally. The case studies would be more precise if the response of consumers 
to particular functional foods were available. 
 
Only one product was studied in the thesis. The importance of this approach to trade 
policy would be enhanced if more products could be studied. Similarly, only two 
countries‘ markets for functional food were examined —  making any general 
extrapolation to global effects imprudent. Since time and resources were limited when 
writing this thesis, a wider study into many other countries may provide deeper 
insight into the general applicability of final results.  
 
6.3 Suggestions for further research 
There are some further research opportunities that have become apparent during the 
work undertaken in this thesis. First, more case studies would provide further 
empirical evidence to corroborate the results. Only two cases of the four developed in 
the trade policy modelling work have been operationalized in the empirical case 
studies in this thesis. Hence, future research could extend to other two cases in order 
to have a full test of the theoretical trade model. Since the market situations assumed 
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in the other two cases differ considerably from those in the case studies, future 
research may have to focus on different products or markets in additional countries.   
 
Secondly, different health economic models could be used in the case studies to better 
evaluate the health care cost savings from selected functional products. In this thesis, 
the COI model is selected for the case studies when calculating the potential health 
care cost savings associated with trans fat free canola/rapeseed oil. The COI model is 
reasonable for this thesis because it has fewer restrictions on the type of data that can 
be used. However, it is a relatively simple approach for evaluating the health benefits. 
A more precise model might be a better choice if the data is available.  
 
Moreover, additional information on consumer attitudes and behavior could assist in 
clarifying the key assumption in the study — the consumer response to functional 
foods. A consumer survey could provide information on the magnitude of the demand 
shifts in the trade model. The consumer survey could also provide information that 
would assist in estimating the substitution away from other products to selected 
functional foods.  
 
Another avenue for further research would be to evaluate policy makers‘ responses to 
the results. Does it provide information that might alter policy decisions? In particular, 
is the ratio, , the correct form to present the results to policy makers?  
 
Last but not least, this thesis provided an analysis of the interaction between trade 
barriers and functional foods. Following the results from this thesis, further research 
may wish to examine policy design and implementation. For example, health and 
trade policy are made in isolation from each other. This thesis might suggest a more 
inclusive policy formulation mechanism.   
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6.4 Conclusion  
The functional food market is increasing rapidly on a global scale and trade policy has 
an important place in the markets for these products. Trade may be inhibited which 
inadvertently lead to consumers and society suffering an unintended loss of benefits.  
 
This thesis provides a link between trade barriers and functional foods — and thus 
between trade policy and health policy. The final result in the case studies confirmed 
the theoretical analysis that there are indeed important forgone benefits associated 
with canola/rapeseed oil arising from existing trade barriers. The thesis is, of course, 
limited in scope and further research is needed for a more comprehensive picture of 
the link between trade barriers and functional foods.  
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APPENDIX 1：EXAMPLES OF FUNCTIONAL 
COMPONENTS
a
 
 
Table A1. Examples of functional foods and associated health benefits 
 
Class/Components Source Potential Benefit  
Carotenoids 
Beta-carotene 
carrots, pumpkin, sweet 
potato, cantaloupe 
neutralizes free radicals, 
which may damage cells; 
bolsters cellular 
antioxidant defenses; can 
be made into vitamin A in 
the body 
Lutein, Zeaxanthin 
kale, collards, spinach, 
corn, eggs 
citrus may contribute to 
maintenance of healthy 
vision 
Lycopene 
tomatoes and processed 
tomato products, 
watermelon, red/pink 
grapefruit 
may contribute to 
maintenance of prostate 
health 
Dietary (functional and total) Fiber 
Insoluble fiber 
wheat bran, corn bran, 
fruit skins 
may contribute to 
maintenance of a healthy 
digestive tract; may reduce 
the risk of some types of 
cancer 
Beta glucan
b
 
oat bran, oatmeal, oat 
flour, barley, rye 
may reduce risk of 
coronary heart disease  
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Soluble fiber
b
 
psyllium seed husk, peas, 
beans, apples, citrus fruit 
may reduce risk of CHD 
and some types of cancer 
Whole grains
b
 
cereal grains, whole wheat 
bread, oatmeal, brown rice 
may reduce risk of CHD 
and some types of cancer; 
may contribute to 
maintenance of healthy 
blood glucose levels 
Fatty Acids 
Monounsaturated fatty 
acids (MUFAs)
 b
 
tree nuts, olive oil, canola 
oil 
may reduce risk of CHD 
Polyunsaturated fatty acids 
(PUFAs)—Omega-3 fatty 
acids—ALA 
Walnuts, flax 
may contribute to 
maintenance of heart 
health; may contribute to 
maintenance of mental and 
visual function 
PUFAs—Omega-3 fatty 
acids—DHA/EPAb 
salmon, tuna, marine, and 
other fish oils 
may reduce risk of CHD; 
may contribute to 
maintenance of mental and 
visual function 
Conjugated linoleic acid 
(CLA) 
beef and lamb; some 
cheese 
may contribute to 
maintenance of desirable 
body composition and 
healthy immune function 
Flavonoids 
Anthocyanins—Cyanidin , 
Delphinidin, Malvidin 
 berries, cherries, red 
grapes bolsters cellular 
antioxidant defenses; 
may contribute to 
maintenance of brain 
function 
Flavanols—Catechins, 
Epicatechins, 
tea, cocoa, chocolate, 
apples, grapes 
may contribute to 
maintenance of heart 
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Epigallocatechin, 
Procyanidins 
health 
Flavanones—Hesperetin, 
Naringenin 
citrus foods  
neutralize free radicals, 
which may damage cells; 
bolster cellular antioxidant 
defenses 
Flavonols—Quercetin, 
Kaempferol, Isorhamnetin, 
Myricetin 
onions, apples, tea, 
broccoli 
neutralize free radicals, 
which may damage cells; 
bolster cellular antioxidant 
defenses 
Proanthocyanidins 
cranberries, cocoa, apples, 
strawberries, grapes, wine, 
peanuts, cinnamon 
may contribute to 
maintenance of urinary 
tract health and heart 
health 
Isothiocyanates 
Sulforaphane 
 cauliflower, broccoli, 
broccoli sprouts, cabbage, 
kale, horseradish 
 may enhance 
detoxification of 
undesirable compounds; 
bolsters cellular 
antioxidant defenses 
Minerals 
Calcium
b
 
 sardines, spinach, yogurt, 
low-fat dairy products, 
fortified foods and 
beverages 
may reduce the risk of 
osteoporosis 
Magnesium 
spinach, pumpkin seeds, 
whole grain breads and 
cereals, halibut, brazil nuts 
 may contribute to 
maintenance of normal 
muscle and nerve function, 
healthy immune function, 
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and bone health 
Potassium
b
 
potatoes, low-fat dairy 
products, whole grain 
breads and cereals, citrus 
juices, beans, bananas 
may reduce the risk of 
high blood pressure and 
stroke, in combination 
with a low-sodium diet 
Selenium 
fish, red meat, grains, 
garlic, liver, eggs 
neutralizes free radicals, 
which may damage cells; 
may contribute to healthy 
immune function 
Phenolic Acids 
Caffeic acid, Ferulic acid 
 apples, pears, citrus fruits, 
some vegetables, coffee 
 may bolster cellular 
antioxidant defenses; may 
contribute to maintenance 
of healthy vision and heart 
health 
Plant Stanols/Sterols 
Free Stanols/Sterols
b
 
corn, soy, wheat, wood 
oils, fortified foods and 
beverages 
may reduce risk of CHD 
 Stanol/Sterol esters
b
 
fortified table spreads, 
stanol ester dietary 
supplements 
 may reduce risk of CHD 
Polyols 
Sugar alcohols
b—Xylitol, 
Sorbitol, Mannitol, 
Lactitol 
some chewing gums and 
other food applications 
 may reduce risk of dental 
caries 
 Prebiotics 
Inulin, 
Fructo-oligosaccharides 
whole grains, onions, some 
fruits, garlic, honey, leeks, 
 may improve 
gastrointestinal health; 
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(FOS), Polydextrose fortified foods and 
beverages 
may improve calcium 
absorption 
 Probiotics 
Yeast, Lactobacilli, 
Bifidobacteria, and other 
specific strains of 
beneficial bacteria 
 certain yogurts and other 
cultured dairy and 
non-dairy applications 
 may improve 
gastrointestinal health and 
systemic immunity; 
benefits are strain-specific 
Phytoestrogens 
Isoflavones—Daidzein, 
Genistein 
 soybeans and soy-based 
foods 
 may contribute to 
maintenance of bone 
health, healthy brain and 
immune function; for 
women, may contribute to 
maintenance of 
menopausal health 
Lignans flax, rye, some vegetables 
may contribute to 
maintenance of heart 
health and healthy immune 
function 
Soy Protein 
Soy Protein
b
 
 soybeans and soy-based 
foods 
 may reduce risk of CHD 
Sulfides/Thiols, Diallyl 
sulfide, Allyl methyl 
trisulfide 
garlic, onions, leeks, 
scallions 
may enhance 
detoxification of 
undesirable compounds; 
may contribute to 
maintenance of heart 
health and healthy immune 
function 
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Dithiolthiones cruciferous vegetables 
may enhance 
detoxification of 
undesirable compounds; 
may contribute to 
maintenance of healthy 
immune function 
Vitamins     
A
c
 
organ meats, milk, eggs, 
carrots, sweet potato, 
spinach 
may contribute to 
maintenance of healthy 
vision, immune function, 
and bone health; may 
contribute to cell integrity 
B1 (Thiamin) 
lentils, peas, long-grain 
brown rice, brazil nuts 
may contribute to 
maintenance of mental 
function; helps regulate 
metabolism 
B2 (Riboflavin) 
lean meats, eggs, green 
leafy vegetables 
helps support cell growth; 
helps regulate metabolism 
B3 (Niacin) 
dairy products, poultry, 
fish, nuts, eggs 
helps support cell growth; 
helps regulate metabolism 
B5 (Pantothenic acid) 
organ meats, lobster, 
soybeans, lentils 
helps regulate metabolism 
and hormone synthesis 
B6 (Pyridoxine) 
beans, nuts, legumes, fish, 
meat, whole grains 
may contribute to 
maintenance of healthy 
immune function; helps 
regulate metabolism 
B9 (Folate)
 b
 
beans, legumes, citrus 
foods, green leafy 
vegetables, fortified breads 
may reduce a woman‘s 
risk of having a child with 
a brain or spinal cord 
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and cereals defect 
B12 (Cobalamin) eggs, meat, poultry, milk 
may contribute to 
maintenance of mental 
function; helps regulate 
metabolism and supports 
blood cell formation 
Biotin 
liver, salmon, dairy, eggs, 
oysters 
helps regulate metabolism 
and hormone synthesis 
C 
guava, sweet red/green 
pepper, kiwi, citrus fruit, 
strawberries 
neutralizes free radicals, 
which may damage cells; 
may contribute to 
maintenance of bone 
health and immune 
function 
D 
sunlight, fish, fortified 
milk and cereals 
helps regulate calcium and 
phosphorus; helps 
contribute to bone health; 
may contribute to healthy 
immune function; helps 
support cell growth 
E 
sunflower seeds, almonds, 
hazelnuts, turnip greens 
neutralizes free radicals, 
which may damage cells; 
may contribute to healthy 
immune function and 
maintenance of heart 
health 
a Examples are not an all-inclusive list.  
b FDA approved health claim established for component. 
c Preformed vitamin A is found in foods that come from animals. Provitamin A carotenoids are found in many 
darkly colored fruits and vegetables and are a major source of vitamin A for vegetarians. 
Source: IFIC, 2006. http://www.ific.org/nutrition/functional/index.cfm   
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APPENDIX 2: CANOLA/RAPESEED OIL  
SHIFTS IN DEMAND 
 
A2.1 the Chinese Canola/rapeseed Oil Shift in Demand  
Recall from Chapter 3, a trade model was developed for functional food market based 
on two assumptions. First, the new product N, is assumed to be produced at the same 
cost as product M by both domestic and foreign suppliers. Second, product N can be 
represented by the same demand curve as product M and that the new health attribute 
does not change its price elasticity and hence no change in the slope of demand curve. 
Thirdly, from the perspective of consumers, more people are willing to buy the new 
health enhancing product N at the same price. Therefore, demand increases shifting 
out the demand curve.  
 
In the Chinese case study, following the same logic, canola/rapeseed oil is assumed to 
benefit from an increase in demand and consumption due to the recent discovery of 
health giving attributes being associated with canola. Currently in China, however, 
there are no accurate surveys or reports on consumers‘ attitudes to canola/rapeseed oil 
consumption since it became well-known for its trans fat-free attribute. Therefore, 
indirect evidence must be used to reveal the consumers‘ behaviors towards trans 
fat-free canola/rapeseed oil. In other words, some way of determining the demand 
shift is needed to undertake calculations for the China case study.  
 
Healthcare Packaging (2007) suggests that functional food product markets are 
booming in the Asia Pacific because of the trend towards health and wellness. 
Consumer demands for convenience products and for healthier and functional 
products show an increasing trend (Taylor and Van Osdol, 2006; Bean, 2006). China's 
―health food‖ industry experienced rapid growth from the late 1980s to the late 1990s, 
with the fastest increase among the urban higher income population (Kotilainen et, al., 
2006). China is leading the way in functional food market expansion in the Asia 
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Pacific region. It is reported that the value of sales of functional foods grew by nearly 
20 percent in 2005 (Healthcare Packaging, 2007). Continued expansion of the 
functional foods market in China is predicted with a two-fold or larger growth in per 
capita spending on functional foods expected between 2004 and 2010 (Benkouider, 
2005).  
 
Therefore, drawing on the reports and information outlined above, four levels of 
demand shift are assumed for the Chinese case study calculation. A base level is 
estimated with a 20 percent increase in demand for canola/rapeseed oil in the Chinese 
market. A two-fold expansion over the base case is set at 40 percent for the medium 
level and an even larger increase of 50 percent is assumed for the most optimistic case. 
Below the base level, a 10 percent shift in demand is assumed. 
 
A2.2 the U.K Rapeseed/Canola Oil Shift in Demand Estimation 
In the UK case study, the two major assumptions made in Case 2 are expected to 
apply. That is, more people are willing to buy canola/rapeseed oil with newly 
recognized health enhancing attributes and consumers are willing to pay at least the 
same price or a premium for higher quality (health enhancing) canola/rapeseed oil. 
Therefore, the increased demand for new health enhancing canola/rapeseed oil shifts 
the demand curve out to D
N
. However, with a GMO import ban, no imports of 
canola/rapeseed oil exist in the domestic market in the UK. Hence, the domestic 
consumption rises to Q
EN
 with higher price at P
E
N. 
 
Rapeseed oil has been the most important vegetable oil produced in the European 
Union since 1988. In 10 years, EU consumption of vegetable oil has risen 50%, 
mainly due to increased consumption of rapeseed oil for its health attributes. 
Currently, rapeseed oil accounts for more than one-third of total European vegetable 
oil production and remains the largest oil consumed in Europe (MATIF, n.d.).. 
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At present, the competition between food consumption and biofuels usage is 
becoming a significant driver of the vegetable oils market and for rapeseed oil in 
particular. Currently, the production capacity for rapeseed is limited in the EU — 
demand in rapeseed oil already exceeds supply. However, the GMO import ban on 
rapeseed/canola oil considerably restricts import sources from other countries and 
further raises the domestic price.  
A report from FEDIOL (2006) shows that the consumption of rapeseed oil in the UK 
market went up 48 percent from 0.43 million tones (Mt) to 0.63 Mt in the last 15 
years (see Table A2).  This increasing rate has slackened a bit in the last 5 years 
because of increases in the rapeseed oil price caused by the high competition for oil 
due to mandated bio-fuel usage. However, rapeseed oil remains the most widely 
consumed vegetable oil in the UK market, particularly since its health enhancing 
attributes became well known in the 1990s.   
 
Table A2. United Kingdom consumption of vegetable oils and fats 
(1000 t) 
 
 Groundnut Soya Rape Sunflower Cotton 
Other 
liquid oils 
2006 6 331 630 194 3 3 
2005 5 248 623 121 3 5 
2004 6 222 629 67 12 4 
2003 8 255 599 96 0 43 
2002 6 194 632 112 0 33 
2001 8 199 740 130 1 16 
2000 7 168 744 163 0 7 
1990 9 133 427 165 1 24 
1980 16 197 136 27 6 5 
Source: FEDIOL (2006). 
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Therefore, the UK case study is consistent with the two major assumptions of the 
model. First, the consumption of rapeseed oil is increasing greatly due to the health 
giving attributes of rapeseed oil. Based on the information in FEDIOL (2006), four 
levels of increased demand are used in the UK‘s case study calculations. A base level 
is estimated using a 30 percent increase in the domestic price for canola/rapeseed oil 
as a functional food in the UK market. A 40 percent change is used for the medium 
level. An even greater increase of 50 percent is assumed for the most optimistic case. 
Below the base level, a 15 percent demand increase is assumed for the most 
conservative case. 
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APPENDIX 3: ESTIMATION AND CALCULATIONS  
FOR THE SAVINGS IN HEALTH COSTS 
 
A3.1 Estimation of daily trans fat intake data in China. 
While no studies on trans fat consumption in mainland China could be found, a study 
on trans fats in locally available foods conducted by the Centre for Food Safety (CFS) 
and the Consumer Council (CC) in Hong Kong, China is available. However, since 
results vary among different tested samples, no single estimate is available for the 
case study. Hence, an average estimate is required. Based on CFS (2007), the average 
trans fat daily intake for four major types of food were calculated.  
 
Combining the total trans fat consumption data from the CFS (2007)‘s study, which 
used samples of 80 varied products, the final calculation of individual daily average 
trans fat intake is shown in table A3.1. Since the tested sample foods are not a major 
proportion of the Chinese diet, consumers may or may not choose all of the above 
four types of foods to include in their diet. Therefore, a 25 percent ratio is assigned to 
provide a conservative estimate. This ratio results in a total of 1.99g TFA daily intake 
for Chinese consumers.  
 
Table A 3.1  Estimated trans fat consumption in China 
 
 
bread 
samples
 a
 
butter-made 
products
 b
 
fried 
products
 c
 
margarine/ 
margarine 
like spreads
 d
 
Total 
Total 
TFA(g)
 e
 
202.7 3.37 1.59 12.4 220.06 
Sample 
size(piece) 
33 25 14 8 80 
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Average 
TFA(g)
 f
 
6.14 0.13 0.11 1.55 7.94 
25% intake
 g
 1.54 0.03 0.03 0.39 1.99 
a
 Bread samples include sliced breads, buns, loaves, croissants and egg tarts. 
 
b Butter-made products includes cakes, waffles, egg puffs and egg rolls. 
c Fried products includes fries, fried chicken and oriental fried food. 
d margarine/margarine like spreads includes butter and margarine/margarine like spreads.  
e TFA is calculated from 100g/sample.   
f Average TFA(g) = Total TFA(g)/ Sample size(piece) 
g As the above sample foods are not frequently found in the common diet in China, it is assumed that there is only 
25 percent chance that people will choose one of above four types foods in their daily diet. This means that 25 
percent of total average TFA is the actual dietary intake assumed. 
 
A3.2 Assumed HCS rate (%)  
A3.2.1 Assumed HCS rate (%) in Chinese case study 
Recall from Section 3.3 in Chapter 3, the discussion on health care costs savings 
(HCS) suggested that it is likely to be some function of the consumption of the 
particular functional food. Therefore, the HCS that would arise from the removal of 
the trade barrier is a function of the increased consumption of product N. That is, 
 HCS = ƒ( ΔQN ),  where ΔQN is the difference between the consumption of N 
with a trade barrier and that which arises without the trade barrier. 
 
Following the analysis in Section 3.2, the difference between the consumption of N 
with a trade barrier and that which arises without the trade barrier is measured by the 
quantity change along the demand curve D
N 
from Pw to (Pw + C). Thus, in the Chinese 
case study, the HCS would arise from the quantity change, which is a function of the 
increased consumption of trans fat-free canola/rapeseed oil along the new demand 
curve.  
 
Known as a functional food, trans fat-free canola/rapeseed oil is found to provide 
health enhancing benefits for consumers. However, prior to the scientific evidence 
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discovered on its health enhancing attributes, canola/rapeseed oil has made health 
contributions to consumers since it was marketed. Therefore, all the people who 
consumed canola/rapeseed oil benefited from its health enhancing attributes and 
society received health savings due to reduced risk of CHD. Among the first three 
steps in section 4.3.2.2, HCS calculations are based on consumption of 
canola/rapeseed oil in the entire domestic market, which is quantity Q
DN‘
. However, in 
this thesis, the health care costs savings (HCS) is designed to determine the health 
improvement effect caused by trade liberalization. That means the HCS calculation 
should be focused on the quantity change of trans fat-free canola/rapeseed oil along 
the new demand curve. In order to limit the calculation to this group of people, a HCS 
rate is introduced into the last step calculation. The HCS rate  is calculated as 
HCS rate = 
'DN
' DN  DN
Q
Q - Q
  and is provided as a percent change — details can 
be found in the Table A3.2.  
 
By introducing the HCS rate in the Chinese case study, calculation for health care 
savings are concentrated on the expansion quantities in the market due to trade 
liberalization. Therefore, only those health care cost savings attributed to trade 
liberalization are included when determining the health care savings.  
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Table A 3.2 HCS rate calculation in Chinese case study 
 
 
High 
(50% demand shift) 
Medium 
(40% demand shift) 
Base 
(20% demand shift) 
Low 
(10% demand shift) 
Q
DN
(Mt)
 a
 6.515 6.080 5.212 4.777 
Q
DN‘
 (Mt)
 b
 6.409 5.981 5.127 4.699 
Q
DN - QDN‘(Mt) 0.106 0.099 0.085 0.078 
HCS rate (%) = 
' DN
' DN  DN
Q
Q - Q
 1.65% 1.66% 1.66% 
1.66% 
a  QDN = QDM * (1+ demand shift rate)  
b QDN‘ is calculated from the following steps using demand elasticity: (Demand elasticity is the same with both demand curves)  
'
'
'
'
)(
)(
)(
)(
DN
W
DNDN
DN
W
WW
DNDN
D
Q
CP
C
QQ
Q
CP
CPP
QQ
Q
P
P
Q 












 
)(*)(
)(*'
CCP
CPQ
Q
D
W
W
DN
DN
ε 

  where 
D  is -0.20, (Pw + C) is 928.68 (US dollar/tonne) and (-C) is -76.68 (US dollar/tonne) from table 4.1 in section 4.3.2.1.
1
1
7
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A3.2.2 Assumed HCS rate (%) in the UK case study 
Applying the same logic from Chinese case study, a HCS rate is also introduced into 
the last calculation step in the UK case study. The HCS rate is calculated as 
 
HCS rate = 
EN
EN  DN
Q
Q - Q
  = 
0.63
0.63 - 0.77
 = 22 percent 
Where Q
DN
 is 0.77 Mt and
 
Q
EN
 is 0.63 Mt from Table 5.3 in Section 5.4.1. 
 
By introducing the HCS rate in the UK case study, calculations for health care savings 
are concentrated on the expansion quantities in the market due to trade liberalization. 
Therefore, only those health care cost savings attributed to trade liberalization are 
included when determining the health care savings.  
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APPENDIX 4: ADJUSTMENT ON 
UK CASE STUDY 
In the Chinese case study, the result of evaluation for potential health care cost 
savings in China is underestimated due to limitation on data. The indirect health cost 
data in China is unavailable from current literatures. Therefore, the final weighting 
ratio could partially reveal the real forgone benefits of trans fat free canola oil 
suffering from trade barriers — 9 percent tariff rate in China. In the UK case study, 
The indirect health cost data in UK is included in the evaluation for potential health 
care cost savings. Thus, the final weighting ratio could completely indicate the real 
forgone benefits of trans fat free canola oil suffering from trade barriers — an 
import ban on GMO in UK.  
 
If simply comparing the both weighting ratio from Chinese case study and UK case 
study, the result might be less convinced because UK case study includes completed 
data than the Chinese case study. In order to make the conclusion supportive, 
unbalanced factor will be eradicated from the UK case study just for the purpose of 
result comparison.      
 
As mentioned in chapter 5, in the United Kingdom, the total costs of CHD are 
approximate £9.0 billion (US$17.82 billon)
35
 in 2006. Of the total cost of CHD to the 
UK, around 36% is due to direct health care cost, 43% to productivity losses, and 21% 
to the informal care of people with CHD (Allender et al., 2008b). From previous 
information, the direct CHD cost that will be accounted in the calculation is around 
£3.2 billion (US$6.34 billon) from the health case system in the UK in 2006. The 
indirect health cost will be removed from calculations in this section. Based on the 
                                                 
35 I use GBP: USD = 1:1.98, based on the current market foreign exchange rate (average, July 7, 2008). 
 120 
calculations in section 5.4.2 of chapter 5, Table 5.6 will be redone by eliminating 
indirect health care cost in the total annual CHD cost. 
 
Table A4.1 potential health-care savings estimated in the UK  
(direct health care cost only) 
 Base High Medium Low 
TC change due to 1 g TFA reduction daily 
(%)
a
 
-1.55 -1.55 -1.55 -1.55 
Daily TFA reduction 0.89 2.22 1.78 0.44 
Total change in TC (%)
b
 1.38 3.44 2.76 0.68 
TC to CHD ratio 
c
 2.0 3.0 2.0 2.0 
Change in CHD (%)
d
 2.76 10.32 5.52 1.36 
CHD to cost ratio 1.0 1.0 1.0 0.5 
Total annual direct CHD cost 
( million U.S dollars)
 e
 
6340 6340 6340 6340 
Total change in annual CHD cost due to 
TFA reduction in daily diet ( million US 
dollars)
 f
 
175 654 350 43 
Health Care Savings (HCS) rate g        22% 22% 22% 22% 
Final direct HCS (million US dollars)
  h 38.5 143.88 77 9.46 
a Total Cholesterol (TC) change is rated at 1.55: 1 due to 1 g of TFA reduction. 
b Total change in TC (%) = TC change due to 1 g TFA reduction daily(%) * Daily TFA reduction (g) 
c The relationship between total cholesterol and CHD is 1:2 based on Expert Panel (1988). For the 1:3 ratio is used 
for high level estimation which assumed to be the long-term ratio. (Source: Malla et al., 2007) 
d Change in CHD (%) = total change in TC (%) * TC to CHD ratio  
e Source: Allender et al., (2008b).  
f Total change in CHD cost = total annual CHD cost * Change in CHD(%) * Change in CHD (%) to change in cost 
(%) ratio 
g See Section A3.2.2 in Appendix 3 for details.  
h HCS = Total change in annual CHD cost * HCS rate (%) 
 
Followed the same step in UK case study, Table 5.7 will be redone by changing HCS 
result from Table A4.1 and keeping all other result unchanged. Table A4.2 shows the 
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calculations undertaken to derive the ratios used in the comparison. From the table, 
the ratios for canola/rapeseed oil are calculated based on the results from the previous 
UK case study and the new HCS calculated above. In summary, in the absence of the 
indirect health cost including to the health benefits calculation of canola/rapeseed oil,    

M
is equal to 1.19 in the base case, 1.05 in the high case, 1.11 in the medium case to 
1.26 in the low case before canola/rapeseed oil has been recognized as functional food 
in the UK market. With the health attributes attaching on canola/rapeseed oil, the ratio 
 
N
  is 1.77 in the base case, 2.28 in the high case, 1.98 in the medium case to 1.64 in 
the low case.  
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Table A4.2 Final ratio calculation in the U.K case study 
(direct health care cost only) 
 
   
Formula 
5
8765
M
 )      (
surplusproducer 
 surplusconsumer  
 
a
aaaa 




 532
118765432
N
   
 HCS  )           (
surplusproducer 
HCS  surplusconsumer  
 
aaa
aaaaaaaa






 
Base 
76.26/64.17 
02.219
5.3861.348 
 
1.19 1.77 
High 
18/17.1 
216
88.14361.348 
 
1.05 2.28 
Medium 
44.44/39.87 
22.215
7761.348 
 
1.11 1.98 
Low 
132.78/105.16 
78.217
46.961.348 
 
1.26 1.64 
 
 
 
N
 
M

